


Inf. Dis

ILL WINDS AND TROUBLED WATERS: SELECTED WHIFFS OF LEGIONELLOSIS

William B. Baine, M.D.

Grand Rounds
Department of Internal Medicine
Southwestern Medical School
The University of Texas Health Science Center at Dallas

March 3, 1983



It is ill arguing with the master of thirty legions.

Favorinus (c. A.D. 130), yielding to the Emperor Hadrian in an argument and paraphrasing the proverb cum principe non pugnandum (avoid contesting with the powerful).

But there went up a mist from the earth, and watered the whole face of the ground.

Genesis ii.6

Prologue

St. Elizabeths Hospital is the United States Government's institutional establishment for the reclamation and treatment of men and women afflicted with loathsome or incurable diseases and insanity in all its phases and of criminal degenerates.

The Book of Washington (1927)

In March 1947 Elizabeth Jackson and her colleagues at the Army Medical Service Graduate School isolated a novel microorganism from a guinea pig that had been inoculated with blood from a colleague, the serologist in the laboratory, who had a mild febrile respiratory illness. At a meeting of the Society of American Bacteriologists five years later, her group reported that the isolate was pathogenic for guinea pigs and embryonated eggs, that it was not susceptible to penicillin, and that it did not grow on any of a variety of bacteriologic media. Since they could detect no complement-fixing antibody in convalescent serum from the patient, they presumed that the strain, designated Olda, was a clinically irrelevant "rickettsia-like agent" that had coincidentally infected one of the guinea pigs in their laboratory (1-3).

Austin, the seat of Mower County in southeastern Minnesota, is an agricultural community that once boasted the largest meat-packing plant in the United States. The city is the home of the Hormel Institute, which conducts research on dietary factors in cardiovascular disease. In the summer of 1957 residents of Austin experienced an outbreak of pneumonia with 78 cases and two deaths. Investigation of the outbreak failed to identify the etiologic agent, its source, or its mode of transmission (4, 5).

The holdings of the colonial Maryland landowner Thomas Cornwallis included the 2000 acres of Saint Elizabeths Manor between Oxon Creek and the Anacostia River. The Government Hospital for the Insane was opened in 1855 on a portion of the old Cornwallis property in what had become the District of Columbia. In 1916 the name of the institution was changed to that of the 17th-Century estate. St. Elizabeths Hospital has played host to such illustrious Americans as Ezra Pound and John W. Hinckley, Jr. In the summer of 1965, 81 cases of pneumonia with 14 deaths occurred in an outbreak among patients there. An epidemiologic investigation provided evidence for airborne transmission of an etiologic agent associated with excavations for a sprinkler system on the grounds, but the agent was not identified (6, 7).

Named for the Ottawa Indian chief, Pontiac, the seat of Oakland County, Michigan, is an automobile manufacturing center. In July and early August 1968 at least 144 persons who had entered the County Health Department were involved in an outbreak of febrile illness characterized by headache and myalgia without pneumonia. The epidemic was linked to exposure to a defective air-conditioning system, and the etiologic agent appeared to be present in the basin of the evaporative condenser used to cool air distributed throughout the building, but the agent was not identified (8-10).

Benidorm, on the Spanish Riviera, is a popular destination for British holiday-makers taking inexpensive package vacations. In the summer of 1973

eighty-nine British tourists from one Benidorm hotel developed respiratory illness, and three died with pneumonia. Investigation of the outbreak by Scottish and Spanish authorities failed to identify the etiologic agent, its source, or its mode of transmission (11-13).

The James River flows 340 miles from Botetourt County, Virginia, to its estuary at Newport News. In the same year as the Benidorm outbreak, ten men who had cleaned a steam turbine condenser on the James developed a febrile illness characterized by headache and myalgia without pneumonia. The etiologic agent was not identified (14, 15).

The Independent Order of Odd Fellows is the American branch of a fraternal benefit society with origins in 18th-Century England. In September 1974, 20 members of the Odd Fellows developed pneumonia after a convention at Philadelphia's historic Bellevue Stratford Hotel. Two died. The outbreak was not brought to the attention of health authorities at the time (16).

In July and August 1976 an epidemic of 221 cases of pneumonia with 34 deaths struck recent delegates to an American Legion convention and other persons who had entered the Bellevue Stratford or walked by it. An epidemiologic investigation suggested that the etiologic agent had been transmitted by the airborne route on the sidewalk in front of the hotel and in the hotel lobby, but initial efforts to identify the agent were unsuccessful (17).

In January 1977 Morris Dumoff, a bacteriologist at McLaren General Hospital in Flint, Michigan, isolated a fastidious gram-negative bacillus from the lung of a patient who had died on New Year's eve after hospitalization for pneumonia. Growth was obtained on an enriched chocolate agar but not on blood agar. Attempts to identify the organism in his laboratory and at the Michigan Department of Health were unsuccessful, and the isolate was forwarded to the Center (now Centers) for Disease Control (CDC) in Atlanta for further evaluation (18).

Among the dozens of researchers at CDC who had sought to determine the etiology of Legionnaires' disease in the summer and autumn of 1976 had been Joseph McDade, a rickettsiologist. McDade had been asked to look for Coxiella burnettii in autopsy material in an effort to exclude Q fever as a diagnostic possibility. He had inoculated lung tissue from fatal cases of Legionnaires' disease into guinea pigs before passage in embryonated eggs. These guinea pigs had rapidly become febrile after inoculation, suggesting the presence of bacteria in the inocula, so McDade had pretreated his eggs with penicillin and streptomycin to inhibit bacterial contaminants. No rickettsiae had been recovered. Microscopical examination of tissues from the febrile guinea pigs had revealed only occasional cocci in the lungs and extremely rare bacilli in the liver and spleen. Bacteriologic culture of the lungs had confirmed the presence of contaminating gram-positive cocci. The bacilli seen in the liver and spleen had not grown (19).

Annoyed by a snide remark about CDC at a Christmas party late in December 1976, McDade resolved to conclude his unfinished business by isolating the apparent contaminants from guinea pig viscera. Reviewing a section from one spleen, however, McDade for the first time found an apparently intracellular cluster of the bacilli. Intrigued by the thought

that these might represent not contaminants but rather a new rickettsial species of etiologic significance, McDade inoculated spleen tissue into embryonated eggs without antibiotics and recovered an unfamiliar organism. 111 persons from the Legionnaires' disease epidemic were found to have developed an antibody response to this agent (20).

It is now clear that the organism identified by McDade, which has been given the name Legionella pneumophila (21), is the same as those isolated by Jackson and Dumoff as well as the etiologic agent of Austin pneumonia, Pontiac fever, steam-turbine-cleaner's disease, and the outbreaks associated with Saint Elizabeths, Benidorm, and the Bellevue Stratford.

Microbiology

Culture Media

L. pneumophila does not grow on conventional bacteriologic media (22). Culture in vitro was first accomplished at CDC (23) using a medium developed for antimicrobial sensitivity testing of Haemophilus influenzae (24)-- Mueller-Hinton agar enriched with hemoglobin and IsoVitaleX (MH1H), a proprietary mixture of nutritional supplements for bacteria. Hemoglobin can be replaced by iron salts, and the essential constituent of IsoVitaleX is L-cysteine hydrochloride (23). F-G agar, Mueller-Hinton agar supplemented with ferric pyrophosphate and L-cysteine hydrochloride, is superior to MH1H for primary isolation of the organism from clinical specimens (23).

A substantial improvement in the ability to recover L. pneumophila directly from clinical specimens is provided by charcoal yeast-extract (CYE) agar (25). The sensitivity of this medium for primary isolation of L. pneumophila is further enhanced in the form of buffered charcoal-yeast extract (BCYE) medium, containing N-2-acetamido-2-aminoethanesulfonic acid (ACES) buffer (26), and by the additional of nutritional supplements including α -ketoglutarate (27) and albumin (28). Incorporation of dyes into BCYE facilitates differentiation of L. pneumophila from other bacteria (29, 30). Some success has been achieved in developing selective media for L. pneumophila by the addition of various antimicrobial agents to inhibit contaminating organisms (27, 31-33).

Microscopy

L. pneumophila is a coccobacillary to filamentous gram-negative bacillus that stains only faintly with saffranin and is more readily seen when carbol fuchsin is employed as the counterstain (22, 34). The modified Macchiavello staining technique for rickettsiae described by Gimenez (35) can also be used but is not specific for Legionella. The organism is not acid-fast (22). Strains that have not been extensively passed on agar media contain presumably lipid-laden sudanophilic inclusions (34). Polar, subpolar, and lateral flagella are demonstrable on bacteria in vitro and in vivo using the silver-plating or Leifson stains for flagella (36-39).

Ultrastructure

Transmission electron micrographs of L. pneumophila reveal the typical

cell envelope of gram-negative organisms, comprising a cytoplasmic membrane, a narrow peptidoglycan layer, and an outer membrane (40-43). The organisms multiply by pinching nonseptate fission (41). The presence of diamino-pimelate, an amino acid characteristic of bacterial cell walls, has been confirmed (44). The ultrastructural characteristics of flagella and fimbriae on the organism have also been described (45, 46). Suggestions that the organism forms spores (47, 48) have not been confirmed (40-43).

Antigens

The antigenic characteristics of L. pneumophila have been extensively studied and include group-specific and species-specific determinants (49). Serogroup specificity appears to be conferred by a lipid-protein-carbohydrate complex surface antigen of high molecular weight that has been partially characterized (50-52). Antigenic relationships with other species of Legionella have been demonstrated by two-dimensional electrophoresis (53). Evidence regarding antigenic characteristics of a capsule-like envelope (54) and of the flagella (55) have also been reported.

Cell Lipids

Among gram-negative bacteria, cells of L. pneumophila are exceptionally rich in branched-chain fatty acids, and the characteristic profile of the methylated fatty acids from the organism revealed by gas-liquid chromatography is useful in confirming the species of the organism (56-59). The content of phospholipids in L. pneumophila cells is also relatively high, and the organism is atypical in that the most prevalent class of phospholipid is phosphatidyl choline (lecithin), which is uncommon among prokaryotes (59).

Fluorophores

Cultures of L. pneumophila elaborate a product that emits yellow-green fluorescence upon excitation with long-wave ultraviolet light (22). At least a fraction of the fluorescent material is soluble (23).

Metabolism

L. pneumophila is an obligate aerobe that does not ferment carbohydrates, although utilization of starch is detectable (34). Glutamate is utilized preferentially as an energy source, whereas glucose appears to be metabolized by the pentose phosphate or Entner-Doudoroff pathways (60). The organism is catalase-positive, gelatinase-positive, weakly oxidase-positive, and urease-negative and does not reduce nitrate (34). Hippurate is hydrolyzed (61).

Various chemically defined media that support growth of the organism have been described (62-65). The simplest of these contains only eight essential L-amino acids plus L-glutamic acid as an energy source, but this medium does not permit optimal growth (66). The organism produces a brown pigment when furnished L-tyrosine in adequate concentrations (67). L-phenylalanine can be substituted for L-tyrosine, but the D-stereoisomers do not support pigment production (68).

A variety of enzymatic activities have been detected in L. pneumophila.

The organism digests egg yolk in a fashion suggesting the activity of protease, lipase, and phospholipase C (lecithinase) (69). Aminopeptidase, esterase, alkaline and acid phosphatase, and phosphoamidase activity have been documented with specific substrates (70, 71). Elaboration of extracellular protease, phosphatase, lipase, deoxyribonuclease, ribonuclease, and β -lactamase and starch-hydrolysing activity has been reported, but doubt has been cast on the presence of extracellular phospholipase C (72). Particular attention has been given to L. pneumophila protease activity, which appears extracellularly and is active against several human serum proteins but not elastin (72-75).

Genetics

L. pneumophila is the type species of the genus Legionella, the sole member of the family Legionellaceae (21). The DNA of the organism has a guanine-plus-cytosine content of 39% the genome size is 2.5×10^9 , comparable to that of Escherichia coli (76). No relationship to any of a large number of previously described bacteria with similar characteristics has been revealed by DNA hybridization studies (21).

Some strains of L. pneumophila bear cryptic plasmids (77-79). One report suggested an association between an 80-megadalton plasmid and surface antigens on the bacterium; plasmid-bearing isolates were recovered from the inanimate environment, but clinical isolates were plasmid-free (80).

Ecology

L. pneumophila is found as a free-living bacterium in natural and artificial collections of fresh water, including lakes (81, 82) and streams (83) and riparian soil (83, 84), cooling towers (83, 85-93) and evaporative condensers (9, 10, 84) for air conditioning systems, and potable water systems (92, 94-8). In nature it has been found in association with cyanobacteria (formerly known as blue-green algae) (82), which can provide all the nutrients required for growth of L. pneumophila in vitro (99) and stabilize L. pneumophila in aerosols (100).

Complement-fixing antibodies to L. pneumophila were not detected in sea from 13 genera of small mammals (101).

Antimicrobial Susceptibility

L. pneumophila produces a β -lactamase bound at the surface of the bacterial cell in the periplasmic space (102, 103). The enzyme is primarily a cephalosporinase. It is most active against cefamandole, moderately active against cephacetrile, cephalixin, cephaloridine, cephalothin, pncicillin G, and ampicillin, and slightly active against cefotaxime. Cephaloglycin, cefoxitin, cefuroxime, and cefsulodin are not inactivated. The enzyme is inhibited by the β -lactamase inhibitors CP-45,899 and clavulanic acid (103).

Antimicrobial susceptibility studies of L. pneumophila in vitro using the agar dilution method with MHH reveal marked susceptibility to rifampin ($\leq 0.01 \mu\text{g/ml}$) as well as susceptibility to cefoxitin, erythromycin, aminoglycosidic aminocyclitols, minocycline, doxycycline, chloramphenicol, ampicillin, penicillin G, carbenicillin, colistin, and trimethoprim-

sulfamethoxazole. The organism is less susceptible to tetracycline, methicillin, cefamandole, cephalothin, and clindamycin and resistant to vancomycin (104).

Tests in supplemented Mueller-Hinton broth indicate susceptibility to cefoxitin, cefuroxime, penicillin G, ampicillin, and carbenicillin and intermediate susceptibility to cephaloridine, cephalothin, and cefamandole (103).

Testing of in-vitro susceptibility by agar dilution in CYE agar indicates greatest activity with erythromycin, rifampin, and rosaramycin. Aminoglycosidic aminocyclitols, chloramphenicol, and cefoxitin are very active, whereas other agents including moxalactam, cefoperazone, and cephalosporins show moderate to little activity (105). Susceptibility in vitro to other macrolide antibiotics has also been reported (106).

On BCYE agar L. pneumophila is highly susceptible to erythromycin, rosaramycin, rifampin, and chloramphenicol, susceptible to ampicillin, carbenicillin, cefoxitin, moxalactam, and aminoglycosidic aminocyclitols, intermediate to resistant to cephalothin and cefamandole, and resistant to penicillin G, oxacillin, clindamycin, and vancomycin (107).

Both gentamicin and erythromycin but not cefamandole demonstrate bactericidal activity against L. pneumophila, whether grown in F-G broth or in human embryonic lung fibroblast cell culture (108).

Work with the original strain of L. pneumophila isolated in 1947 suggested resistance to penicillin in ovo (1), but McDade did not recover the organism from eggs pretreated with penicillin and streptomycin (19). More recent tests of antimicrobial susceptibility in embryonated eggs indicate greatest prophylactic efficacy with rifampin, gentamicin, streptomycin, erythromycin, sulfadiazine, chloramphenicol, and cephalothin and, to a lesser extent, oxytetracycline. Chlortetracycline and ampicillin are ineffective. Therapeutic efficacy in infected embryos is greatest with rifampin and erythromycin and present with gentamicin, streptomycin, sulfadiazine, and chloramphenicol (109).

Erythromycin and rifampin were effective in treating guinea pigs experimentally infected with L. pneumophila by the intraperitoneal route, but no significant effect was observed with penicillin, tetracycline, gentamicin, or chloramphenicol, although the dose of the last antibiotic may have been inadequate (110).

Epidemiology

Seroepidemiology

Yoncke et al. detected antibody to a mixture of three strains of serogroup 1 by indirect hemagglutination in 16.8% of 1200 sera submitted for premarital and preemployment syphilis serology in Michigan. Antibody prevalence was higher in sera collected in the summer than in sera collected in winter and decreased with increasing age of the donor after the fourth decade. Antibody prevalence to antigens of serogroups 2-4 ranged from 1.7-6.2% in the same specimens (111).

The prevalence of antibody in healthy persons detected by indirect immunofluorescence (IFA) appears to vary with location. None of a group of Pennsylvania health department employees had titers ≥ 64 (20). Serum from persons in various occupational groups in Nottingham, England had titers ≥ 64 and ≥ 128 in 0.54% and 0.10% of specimens, respectively (112). Only 1.7% of serum specimens from middle-aged and elderly persons in four cities in the United States had titers ≥ 64 (113). Titers ≥ 128 were found in 4% of 156 office workers near the Veterans Administration Wadsworth Medical Center in Los Angeles (114). Control subjects in Kingsport, Tennessee, had a 5.2% prevalence of IFA titers ≥ 128 (89). Of 110 industry employees in Burlington, Vermont, 15% had titers ≥ 128 (87). The same prevalence was observed in hotel employees in Bloomington, Indiana (83). Of 21 employees of hotels near the one associated with the outbreak in Benidorm, 19% had titers ≥ 128 (13). Healthy control subject in Austin, Minnesota, had a prevalence of indirect immunofluorescence antibody (IFA) titers ≥ 64 of 43% (5).

One group of asthmatic patients had a higher prevalence of antibody to L. pneumophila serogroup 1 than did other patients with chronic pulmonary disease or healthy adults (115).

IFA titers ≥ 128 to serogroup 1 of L. pneumophila were found in only 3.4% of patients from whom serum specimens had been submitted to CDC for Pneumocystis carinii serology and in only 1 of 48 patients undergoing bone marrow transplantation (116).

Outbreaks in the Community

Outbreaks of legionellosis (Table 1) have been associated with specific buildings, including hotels (11-13, 16, 17, 91, 98), office buildings (9, 10, 117), a student union (83), a clubhouse (84), and a meat-packing plant (5).

Table 1. Selected Outbreaks of Legionellosis in the Community (88)

Year	Months	Location	Cases	Attack rate (%)	Case-fatality rate (%)	Reference
1957	June-August	Austin, MN	78	0.3	2.6	5
1968	July-August	Pontiac, MI	144	95	0.0	9
1973	July	Benidorm (SP)	89		3.4	13
1973	August	James River, VA	10	100	0.0	15
1974	September	Philadelphia, PA	20	2.9	10.0	16
1976	July-August	Philadelphia, PA	221	6.8	16.1	17
1977	August-September	Kingsport, TN	33	0.6	9	89
1977	May-December	Burlington, VT	69		25	87
1977						
-78	May-August	Bloomington, IN	39	0.2	10	83
1978	August-September	New York, NY	38		8	117
1978	August-September	Dallas, TX	18	6	0.2	118
1979	June-July	Eau Claire, WI	13	0.3	31	91
1980	March	San Francisco, CA	14	2.4	0.0	119
1980	June-September	Lido di Savio (IT)	23	8.7	7.9	98

Endemic Occurrence

Over a 13-month period Macfarlane and colleagues in Nottingham, England, prospectively studied all patients aged 13-79 years admitted to the City Hospital with community-acquired primary pneumonia. Seroconversion to L. pneumophila serogroup 1 was observed in 16 (13%) of 127 patients, with cultural confirmation in one. Two additional cases of seroconversion to L. micdadei and one to L. bozemanii were also documented. Serologic testing for infection with serogroups 2-6 of L. pneumophila and with L. dumoffii and L. gormanii was unrevealing. Evidence of concurrent pneumococcal infection was present in six of the 19 patients with Legionella infection (120).

L. pneumophila was the etiologic agent in 15% of 58 cases of community-acquired pneumonia seen over 11 months at the Pittsburgh Veterans Administration Center (121).

Nosocomial Infection

Nosocomial legionellosis has been a persistent problem in some centers. The largest series of cases of L. pneumophila infection from a single hospital has come from the Veterans Administration Wadsworth Medical Center in Los Angeles, where a persistent environmental focus of the organism led to 65 cases in patients and employees between May 1977 and December 15, 1978 (122-4).

L. pneumophila was the etiologic agent in 30% of 74 cases of nosocomial pneumonia seen over 11 months at the Pittsburgh Veterans Administration Medical Center (121). Legionellosis was diagnosed from autopsy material in 3.8% of a sample of 263 persons dying of nosocomial pneumonia in 40 hospitals in 24 states (125).

Outbreaks of nosocomial legionellosis have occurred in hospitals in the United States and Europe (7, 85-87, 90, 92, 94-97, 126, 127) (Table 2).

Table 2. Selected Outbreaks of Nosocomial Legionellosis (88)

Year	Months	Location	Cases	Attack rate (%)	Case-fatality rate (%)	Reference
1965	July-August	Washington, DC	81	1.4	17.0	7
1977	July-September	Columbus, OH	15		7	85
1977-78	May-July	Los Angeles, CA	49	0.5	31	126
1976-79		Norwalk, CT	28	0.7	38	88
1978	August-September	Memphis, TN	39	2.8	13	90

Seasonality

Outbreaks (Table 1) and sporadic cases (128) of legionellosis are concentrated in the summer and early autumn (88).

Legionella infection was demonstrated in nearly half of the primary community-acquired pneumonia seen at Nottingham City Hospital from July through September but was found in no more than 10% of cases admitted during the rest of the year (120).

In hospitals with persistent problems with nosocomial L. pneumophila infection, cases have occurred throughout the year (86-88, 124).

Mode of Transmission

Fear death?--to feel the fog in my throat,
The mist in my face.

Browning, Prospice

The most important mode of transmission of Legionella infection appears to be by the airborne route (88). At Saint Elizabeths hospital illness was concentrated in patients who either slept by windows left open during the hot Washington summer or had permission to walk about the hospital grounds (7). Even before the etiologic agent of the 1976 Philadelphia outbreak was recognized, the epidemiologic characteristics of the outbreak were judged to be most consistent with airborne transmission (17).

In many instances, outbreaks have taken place in a settings in which exposure occurred to evaporative condensers or cooling towers, which are heat-rejection devices for air-conditioning systems. These devices, which are different in structure and operation from the familiar small window-mounted air conditioners, range in size from the small units seen on the roofs of drug stores and small office buildings to the giant hyperbolic natural draft towers familiar from photographs of nuclear power plants. Evaporative condensers and cooling towers share two characteristics that are incidental to their design: they wash particulate matter from large volumes of ambient air and they expel aerosols of particulate-laden water. Thus samples of any bacteria that are wafted into the air around one of these devices will be washed into a reservoir of warm water inside, and any such bacteria that can persist or multiply in this environment will be present in the aerosol plume forced out of the device (129).

An outbreak at an Atlanta country club was restricted to frequent golfers who were exposed to the exhaust from an evaporative condenser from which L. pneumophila was subsequently recovered (84). An cluster of cases that chiefly involved persons who had used one of the meeting rooms in a hotel occurred in a setting in which exhaust from a contaminated cooling tower traveled down a chimney and through an open damper into the room (91). The clearest evidence of a causal role for a heat-rejection device was obtained in studying an outbreak in a Memphis, Tennessee, hospital. The outbreak was temporally associated with the activation of a disused auxiliary cooling tower when the main units were put out of commission by a flood. Cases were concentrated in areas of the hospital that exposed to the exhaust from the suspect unit, from which L. pneumophila was recovered (90). A particularly striking example of the risk associated with contaminated cooling towers occurred in Burlington, Vermont, when a unit was inadvertently activated while a maintenance worker was still inside it. He promptly developed Legionnaires' disease.

Airborne transmission is also responsible for outbreaks of Pontiac fever. In the original outbreak, illness occurred only in persons exposed to the Oakland County Health Department when the air conditioning was operating. Air discharged from the evaporative condenser, later shown to be a source of L. pneumophila, gained access to the building air supply through cracks in the exhaust and supply ducts in the building and by recirculation on the rooftop (9). The presence of aerosols of L. pneumophila in the building was documented by recovery of the organism from guinea pigs caged in the building but not from similarly placed animals provided with filtered air supplies (10). No recurrences occurred after the air conditioning system was replaced (9).

Nosocomial transmission of legionellosis may occur through generation of aerosols by respiratory therapy equipment using contaminated potable water (96). The potential of showers to serve as generators of infectious aerosols when the water supply of the hospital is contaminated is also a source of concern, although the importance of shower aerosols remains speculative (95).

The weight of evidence suggests that secondary transmission of infection from person to person rarely, if ever, occurs (5, 9, 17, 88).

Age

Attack rates of clinical illness are highest in the middle-aged and elderly (5, 17, 88, 93, 128). Occasional cases in children have been documented (128, 130, 131).

Sex

Attack rates of clinical illness in outbreaks (5, 17, 87, 88) and sporadic cases (88, 128, 132, 133) are higher in males than females.

Smoking

Forty per cent of the 65 cases reported from Wadsworth Medical Center were current cigarette smokers (124). Cigarette smoking has repeatedly been shown to be a significant risk factor (17, 87, 88), even in comparisons with control subjects who had pneumonia that was not caused by L. pneumophila (132), a group that itself would be expected to have an excess of smokers.

Alcohol

Heavy alcohol use has been shown to be a risk factor in sporadic Legionnaires disease (132), although no significant correlation of illness with reported alcohol consumption was found in the study of the Legionnaires' outbreak in 1976 (17).

Underlying Illness

The importance of L. pneumophila as an opportunistic pathogen has been most evident in reports of nosocomially acquired infection. Thirty-six per cent of cases diagnosed in Burlington, Vermont, in 1977 were in immunosuppressed patients (87). In the series of nosocomial legionellosis reported from the Wadsworth Medical Center, 61 (94%) of 615 cases had underlying

medical problems, including immunosuppression (42%), heart disease (35%), cancer (29%), lung disease (25%), and kidney disease (22%) (124), and the additional risk associated with immunosuppression was documented epidemiologically (126).

Underlying immunosuppressive illness may also be a risk factor in community-acquired infections (128), although it is difficult to exclude the influence of referral bias on the method of case ascertainment. That is, diagnostic evaluation of a case of pneumonia is likely to be most thorough in the immunosuppressed host, so immunosuppressed patients are probably overrepresented in collections of cases of laboratory-proven Legionnaires' disease. No association with immunosuppression was found in one study of sporadic cases that was specifically designed to minimize the influence of referral bias (130).

Travel

The large numbers of outbreaks reported in recent hotel lodgers emphasize the frequency with which recent travel is a part of the history of persons with Legionnaires' disease (11-13, 16, 17, 83, 88, 98, 118). Legionnaires' disease has been an unwelcome addition to the schedule of summer vacationers in southern Europe (13, 131). Recent travel was significantly associated with Legionnaires' disease in a case-control study designed to minimize ascertainment bias arising from any tendency to obtain extensive diagnostic tests in cases of pneumonia with a history of recent travel (130). Several hypotheses to explain the risk posed by travel have been proposed but not tested (130): Travel may take susceptible adults to endemic areas. Travel may increase exposure to excavation sites and to public buildings with contaminated cooling towers. Finally, the stress of travel may simply lower resistance to infection in a nonspecific fashion.

Construction and Excavation

Numerous anecdotes of sporadic cases of infection after exposure to excavation or construction sites have raised the question as to whether these activities sometimes generate infectious aerosols from Legionella organisms in the soil (88). The cases of legionellosis at Saint Elizabeths hospital occurred in patients housed near excavations that were in progress for the installation of a sprinkler system (7). The extended outbreak at Wadsworth Medical Center in Los Angeles began within two months of the opening of the new hospital in a setting of uncovered excavation sites (124, 126). Residence near a construction or excavation site has been found to be a risk factor in a case-control study of sporadic cases of legionellosis (132).

Clinical Manifestations

Pontiac Fever

Our concept of the clinical course of Pontiac fever is dominated by the observations made on the cases in the original outbreak in 1968. This form of legionellosis is an acute self-limited febrile illness with an incubation period of approximately 36 hours. It is characterized by malaise, myalgias, and headache lasting two to five days but often followed by more protracted

asthenia in convalescence (Table 3). Respiratory symptoms are minimal to absent in most cases. There are no fatalities (9).

Table 3. Selected Clinical Manifestations in Pontiac Fever

Finding	Prevalence (%)
Malaise	97
Myalgias	95
Headache	88
Fever	86
Chills	83
Dizziness	51
Cough	46
Arthralgias	42
Nausea	42
Meningismus	39
Chest Pain	38
Sore Eyes	30
Sore or Dry Throat	28

Physical examination is unremarkable except for the presence of fever, usually below 39.5°, and transient tachycardia and tachypnea. Urinalysis may reveal minimal proteinuria, hematuria, or pyuria, but these findings are of uncertain significance. There is a polymorphonuclear leukocytosis, with counts as high 17,700 WBC/ μ l reported. No abnormalities in blood chemistries have been recognized, and there are no electrocardiographic or radiologic abnormalities (9).

At Pontiac, 95% of exposed employees and 29% of documented visitors to the building became ill (9), and all of the workmen at risk in the James River episode developed symptoms (14, 15). Because of the mild and nonspecific character of the clinical illness, sporadic cases and even outbreaks with low attack rates are almost certain to escape recognition. It should be noted that the brief incubation period and the absence of radiologically apparent pulmonary involvement suggest that Pontiac fever is not simply mild Legionnaires' disease (10).

One possibility is that this syndrome may arise from absorption of toxic extracellular products of the organism through the respiratory tract. However, the incubation period and apparent absence of pneumonitis are inconsistent with findings observed with experimental aerosolization of endotoxin to rabbits (134). Furthermore, patients with Pontiac fever develop antibody to surface antigens of L. pneumophila, suggesting that they are indeed exposed to intact bacteria (10).

There is no evidence that antimicrobial therapy has any beneficial effect in Pontiac fever (9).

Incubation Period

Data from the 1976 outbreak of Legionnaires' disease in Philadelphia indicated that most cases occurred after an incubation period ranging from

two to ten days (17), and data from other outbreak investigations are consistent with this interval (7, 16, 83, 90).

Prodrome and Respiratory Symptoms

Patients frequently complain of anorexia, malaise, and weakness in addition to respiratory and other systemic symptoms (Table 4) (124, 135).

Table 4. Common Symptoms in Legionnaires' Disease

Proportion (%) with:

Malaise	89			55			
Cough	86	69	92	80	77	79	75
Chills	74	72	77	50	69	79	88
Night sweats					64		
Dyspnea	59		36				
Myalgias	55	46		14		79	
Headache	53	54	28	41		93	38
Chest pain	52	36	33		43		
Sputum production	50	37			36		
Vomiting	23	19					
Number of cases	123	78	61	56	27	14	8
Reference	135	5	124	86	89	119	84

Virtually all the patients reported from Wadsworth Medical Center had a cough, which was usually mild and occasional, unlike the constant hacking cough of Mycoplasma pneumoniae infection. Initially it was dry in most patients, but production of nonpurulent or minimally to moderately purulent secretions ensued in 59% of those with cough. Two-thirds of those with cough had minimal to gross hemoptysis. Recurring shaking chills began within the first three days of illness. Chest pain was usually pleuritic. Symptoms of upper respiratory infection were rare (124).

Emphasis has been placed on the prodrome of Legionnaires' disease, which resembles that of a viremia (136), and on the absence of antecedent upper respiratory tract symptoms (137) in this airborne infection to distinguish legionellosis from pneumonia caused by other common pathogens. Yu and colleagues have cast doubt on the concept that distinctive clinical and laboratory abnormalities exist in legionellosis to help the clinician recognize which cases of pneumonia are likely to be caused by L. pneumophila (121), however scrutiny of their data reveals that the chief difficulty lies in identifying nosocomial legionellosis in the midst of other cases of hospital-acquired pneumonia.

Diarrhea

Watery diarrhea may be observed with onset either early or late in the illness and may even be a prodromal complaint (124) (Table 5).

Diarrhea was reported by 21% of the ill persons in the original outbreak of Pontiac fever (9).

Table 5. Occurrence of Diarrhea in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with diarrhea (%)</u>	<u>Reference</u>
123	41	135
78	13	5
61	47	124
56	13	86
32	25	121
27	24	89
14	36	119
8	13	84

Abdominal Pain

Patients with legionellosis may complain of abdominal pain (Table 6).

Table 6. Occurrence of Abdominal Pain in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with abdominal pain (%)</u>	<u>Reference</u>
123	20	135
61	0	124
56	7	86
15	47	138

Abdominal pain was reported by 24% of the ill persons in the original outbreak of Pontiac fever (9).

Encephalopathy

Depression, emotional lability, confusion, disorientation, delirium, lethargy, and obtundation are among the abnormalities in mental status seen in patients with L. pneumophila infection (124, 135) (Table 7).

Table 7. Occurrence of Neurologic Dysfunction in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with neurologic disorders (%)</u>	<u>Description</u>	<u>Reference</u>
113	21	"depressed mental state or agitation"	135
61	38	"neurologic findings"	124
56	0	[excepting headache]	86
32	45	"neurologic signs"	121
27	59	"confusion, delirium, or obtundation"	90
24	46	"neurologic symptoms and signs"	138
14	36	"confusion"	119
7	57	"marked abnormality of mental status"	139

Confusion was reported by 19% of the ill subjects in the original outbreak of Pontiac fever (9).

Physical Examination

The typical case of *L. pneumophila* pneumonia presents as an acutely ill febrile patient (135). High fever is common. Nineteen per cent of 123 patients from the 1976 Philadelphia outbreak had a fever over 40.0° on admission (135). The maximum temperature in 63 patients reported from Wadsworth Medical Center was 40° or higher in 62% and 40.5° or higher in 19% (124). The fever characteristically has an insidious onset and a continuous configuration and is minimally affected by antipyretics. Relative bradycardia is common (Table 8) (124, 135).

Physical examination of the chest at the onset of illness is often normal, and rales are typically the first abnormality noted, with signs of consolidation supervening (124).

Table 8. Physical Findings in Legionnaires' Disease

Proportion (%) with:

Fever	97	94	99	96	100	100
Tachypnea		42				
Tachycardia		30				
Relative bradycardia			60*			
Number of cases	123	78	61	56	14	8
Reference	135	5	124	86	119	84

*Of 48 patients

An initial respiratory rate ≥ 30 and an initial pulse > 110 were associated with relative risks of fatal outcome of 5.8 and 4.4, respectively, in the 1976 Philadelphia outbreak (135).

Urinalysis

Pyuria, proteinuria (124), and hematuria (135) have been reported in a substantial proportion of cases (Table 9).

Table 9. Findings on Urinalysis in Legionnaires' Disease

Proportion (%) with:

Hematuria	48	0	20
Cylindruria	33		
Proteinuria	25	45	40
Pyuria	16		
Number of cases	102	33	5
Reference	135	119	84

Hematuria is associated with an unfavorable prognosis (135).

Hematology

Lymphopenia and, in patients without underlying hematologic disease, leukocytosis with supranormal numbers of band neutrophils are common in legionellosis (5, 124, 136), although rarely leukopenia may appear to be the result of Legionella infection itself (124) (Table 10). Miller has proposed that lymphopenia ($> 1000/\mu\text{l}$) in the absence of marked neutrophilia is suggestive of pneumonia caused by L. pneumophila (136).

Table 10. Hematologic Findings in Legionnaires' Disease

Proportion (%) with:					
Leukocytosis	53	79	78	82*	70
Lymphopenia ($< 1000/\mu\text{l}$)				53	
Number of cases	117	78	58	56	23
Reference	135	5	124	86	138

*Of 40 patients with leukocytosis

In the 1976 Legionnaires' epidemic a differential count with more than 10% bands and a leukocytosis $> 14,000/\mu\text{l}$ were associated with relative risks of fatal outcome of 3.3 and 2.5, respectively (135).

Hyponatremia

Hyponatremia, usually mild and apparently the result of inappropriate antidiuretic hormone secretion, is common in L. pneumophila infection (124, 135) (Table 11).

Table 11. Occurrence of Hyponatremia in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with hyponatremia (%)</u>	<u>Reference</u>
123	31	135
55	54	124
32	45	121
23	43	138
15	67	136

A serum sodium concentration ≤ 130 mEq/l on admission to the hospital was associated with a relative risk of 2.4 of fatal outcome in the 1976 outbreak (135).

Hypophosphatemia

Hypophosphatemia may be seen early in the course of infection (124) (Table 12), although this finding may not be more common in legionellosis than in other forms of pneumonia (137).

Table 12. Occurrence of Hypophosphatemia in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with hypophosphatemia (%)</u>	<u>Reference</u>
43	51	124
16	31	138

Renal Function

Kirby and colleagues noted no increase in serum urea nitrogen and creatinine in their patients (124), but azotemia and even renal failure have been reported in other series (Table 13).

Table 13. Occurrence of Azotemia in Legionnaires' Disease

<u>Number of patients</u>	<u>Proportion with azotemia (%)</u>	<u>Reference</u>
123	15	135
23	30	138
10	0	10

In the Philadelphia outbreak of 1976, presentation to the hospital with a serum urea nitrogen > 20 mg/dl or serum creatinine > 2.0 mg/dl were associated with relative risks of fatal outcome of 4.8 and 4.5, respectively (135).

Liver Function Tests

Abnormal lactic dehydrogenase (LDH), alanine aminotransferase (SGOT), alkaline phosphatase, and bilirubin levels are commonly seen (135, 136) (Table 14).

Table 14. Liver Function Tests in Legionnaires' Disease

Proportion with high:

LDH	88% (36/41)		
SGOT	49% (21/43)		90% (9/10)
Alkaline phosphatase	49% (20/41)	45% (10/22)	
SGPT		24% (4/17)	
Bilirubin	15% (7/47)	30% (7/23)	
Reference	124	138	137

Helms and colleagues found high SGOT values to be more common in patients with legionellosis than in cases of pneumococcal or mycoplasmal pneumonia (137).

Creatine Phosphokinase

Sharrar and associates reported high creatine phosphokinase (CPK) levels

in five of six sporadic cases of Legionnaires' disease, but elevated CPK determinations have been very unusual in larger series (124, 135).

Arterial Blood Gases

Arterial blood gas measurements reveal hypoxemia and hypocarbia commensurate with the radiographic extent of pneumonia (84, 124). Respiratory failure is the commonest mode of death. In the Legionnaires' outbreak 15 (12%) of 123 patients had an initial $P_{a}O_2 < 50$ torr; nine died. Nineteen (15%) of the 123 eventually required mechanical ventilation; the case-fatality rate in this subgroup was 68%. The relative risk of fatal outcome associated with presentation with hypoxemia or eventual development of respiratory failure were 2.8 and 5.2, respectively (135).

Cold Agglutinins and Other Serologic Tests

Kirby and associates reported reciprocal cold agglutinin titers of 16 in 2 of 16 patients and high *M. pneumoniae* complement fixations titers in 2 of 16 (124). No cold agglutinins were found in sera from the Austin pneumonia outbreak (5).

Examination of Respiratory Secretions

Sputum is characteristically thin and watery or mucoid at the onset of pneumonia. Polymorphonuclear leukocytes are less common than erythrocytes and macrophages, and acellular material is most common. Polymorphonuclear cells become more frequent several days after institution of antibiotic therapy (140). Gimenez stains (35) of specimens are less sensitive than direct immunofluorescence (DFA), and Gram's stain is neither sensitive nor specific (140). The combination of hemoptysis and pleuritic chest pain is not infrequent, and differentiation from pulmonary embolism with infarction may be impossible at the bedside (124, 135).

Kirby et al. reported the results of microscopical examination of 29 transtracheal aspirates; there were few polymorphonuclear leukocytes in 10, moderate to many polymorphs in 17, and mononuclear cells in 2 (124).

Pleural Fluid

Kirby et al. reported results on 13 patients who underwent thoracentesis. Total protein and LDH levels suggested an exudate in eight of ten specimens. The mean leukocyte count was 6,600/ μ l, with a range of 554-32,500/ μ l; polymorphonuclear leukocytes usually predominated (124).

Bronchoscopy

Thin, watery secretions without purulence were found in each of 11 patients undergoing bronchoscopy; mucosal hyperemia and inflammation were noted in four (124).

Cerebrospinal Fluid

Cerebrospinal fluid is almost invariably normal (124, 135).

Radiography

Characteristically, a unilobar patchy alveolar infiltrate extends locally with or without subsequent involvement of other lobes. Progression of the infiltrate may continue for as many as five days after institution of erythromycin therapy, even in the face of other evidence of clinical improvement. Significant improvement in the radiograph is usually observed within two weeks, although several months may be required for full radiographic resolution. Small pleural effusions are common and occasionally precede the appearance of an infiltrate. Mediastinal adenopathy is not seen (124, 135, 141).

Although uncommon, cavitory lung disease can occur in L. pneumophila pneumonia, particularly in immunocompromised patients (142-144).

Among those hospitalized in the Austin pneumonia outbreak, radiographic abnormalities were most common in those aged 40 years or older (5).

Extrathoracic Infection

Histopathologic evidence of extrathoracic infection is uncommon in patients dying of Legionnaires' disease (124), but cases of pyelonephritis (145), peritonitis (146), perirectal abscess (147), hemodialysis fistula infections (148), and disseminated infection (149) with L. pneumophila have all been reported.

Concomitant Infection

The isolation of other potential pathogens from clinical specimens does not exclude simultaneous infection with L. pneumophila (124, 140). Concomitant infections with both L. pneumophila and Mycobacterium tuberculosis (150), L. micdadei (144), or cytomegalovirus (124) have been documented.

Other Syndromes

Despite the association of L. pneumophila with cooling towers and evaporative condensers, serologic data do not support an association with hypersensitivity pneumonitis (151).

Pathology

Post-mortem examination reveals bronchopneumonia with consolidation and hepatization. The carinal and hilar nodes may be enlarged. There is an intraalveolar exudate of polymorphonuclear leukocytes, macrophages, red blood cells, and fibrin. L. pneumophila is visible extracellularly as well as within macrophages. Blood vessels walls and large bronchi are spared. Adrenal lipid depletion and adrenal hemorrhage is sometimes observed (124, 152, 153).

L. pneumophila does not stain with conventional tissue Gram's stains but is readily but nonspecifically visualized with modification of the Dieterle silver impregnation stain (154, 155).

Pathogenesis

Experimental Infections

Davis et al. have developed an experimental model of Legionnaires' disease in which guinea pigs and rats are exposed to aerosols of L. pneumophila in a specially constructed chamber. Nebulization of approximately 7×10^9 colony-forming units reproducibly yields histologically detectable pneumonia in animals of both species, although illness is more severe and fatal infection more common in guinea pigs. L. pneumophila begins exponential growth in the lungs of both species without an appreciable lag phase. Infiltration of polymorphonuclear leukocytes and then mononuclear cells into involved areas begins after 24 to 48 hours, but growth of the organism continues for three to six days despite an increase in the inflammatory response (156).

Guinea pigs but not mice, rabbits, and rhesus monkeys developed pneumonia on exposure to the Oakland County Health Department at the time of the investigation of the original Pontiac fever outbreak. Naturally and artificially exposed guinea pigs had a nodular bronchopneumonia that underwent central necrosis and eventual fibrous encapsulation (10).

Endotoxin

L. pneumophila cells and cell-free products are potent activators of Limulus amoebocyte lysate gelation, a sensitive but not specific test for bacterial lipopolysaccharide (157). However, the febrile response of rabbits injected intravenously with these bacterial products is slight (157), and L. pneumophila shows little potency in other bioassays of endotoxin activity (158). Nonetheless, Fumarola and his associates have demonstrated generation of procoagulant activity by human monocytes exposed to L. pneumophila and related organisms (159), as occurs when monocytes are stimulated by E. coli lipopolysaccharide.

Cytotoxin

A low-molecular-weight extracellular product that is toxic for Chinese hamster ovary cells has been identified (160). This substance has impaired hexose monophosphate shunt activity and oxygen consumption by human polymorphonuclear leukocytes during phagocytosis and reduces iodination and killing of test bacteria in vitro (161).

Hemolysin

Cultures of L. pneumophila show hemolytic activity (69), and sterile filtrates of plasma and urine from experimentally infected rabbits lyse guinea pig red cells (162). Hemolytic activity is present in the macromolecular fraction of concentrated supernates of L. pneumophila cultures (163).

Dopa

L. pneumophila appears to possess the enzyme tyrosine-5-monooxygenase, which catalyzes the conversion of tyrosine to dihydroxyphenylalanine (dopa)

(67, 68, 164). Thus one component of pulmonary infection with this organism may be liberation of dopa into the systemic circulation, with possible effects on the central and autonomic nervous systems.

Host Defense Mechanisms

Antibody

Infection with L. pneumophila stimulates an antibody response. The immunoglobulin classes involved vary between individuals (165).

L. pneumophila maintained by passage in ovo are resistant to the bactericidal effect of human serum even in the presence of specific antibody, which is required to fix complement to the surface of these bacteria (166). However, mice and guinea pigs passively immunized with specific IgG raised by immunization with the antigen characterized by Wong et al. were protected against experimental challenge with the organism (50).

Phagocytosis

Optimal phagocytosis of L. pneumophila by human polymorphonuclear leukocytes requires both complement and specific antibody. These phagocytes kill L. pneumophila only in the presence of complement and specific antibody, but bacterial killing is incomplete, however polymorphonuclear cells do not support the growth of L. pneumophila (166).

In contrast, L. pneumophila multiplies within membrane-bound cytoplasmic vacuoles of human monocytes in vitro under conditions that do not permit extracellular multiplication (167). Specific antibody promotes the binding of L. pneumophila to monocytes. Monocytes require both specific antibody and complement to kill L. pneumophila but, as in the case of polymorphonuclear leukocytes, killing is incomplete. In contrast to polymorphs, monocytes permit the growth of L. pneumophila, even in the presence of antibody and complement, under conditions that do not permit extracellular multiplication (167, 168).

Cell-Mediated Immunity

Human monocytes in cell culture inhibit multiplication of L. pneumophila if incubated with both human lymphocytes and concanavalin A or with cell-free supernates of concanavalin A-sensitized mononuclear cells. The activated monocytes inhibit multiplication by ingesting fewer bacteria than do nonactivated monocytes and slowing the rate of intracellular replication of L. pneumophila (169).

Laboratory Diagnosis

Primary Isolation

Primary isolation of L. pneumophila from contaminated environmental and clinical specimens was initially performed after passage in guinea pigs and embryonated eggs (10, 20).

Edelstein et al. reported positive cultures on CYE agar from endotracheal and transtracheal aspirates, lung tissue, and blood but not from pleural fluid. Cultures from respiratory tract secretions required three to seven days to become positive (140). L. pneumophila may still be isolated from respiratory secretions or lung days after initiation of erythromycin therapy (140, 170).

Recovery of L. pneumophila from lung tissue may sometimes be enhanced by dilution of the specimen before culture on agar media (170).

Antigen Detection

Antigenuria has been detected in patients with L. pneumophila infection by radioimmunoassay (171), enzyme-linked immunosorbent assay (172, 173), and latex agglutination (174).

Direct Immunofluorescence

DFA (direct fluorescent antibody) may be used to detect the organism in environmental and clinical specimens, including respiratory secretions and tissue from biopsies and autopsies (175, 176). By definition, DFA staining is serogroup-specific. Organisms belonging to serogroups not encompassed by the reagents used by a particular laboratory will stain poorly or not at all. Seven serogroups of L. pneumophila have been described (177), and recognition of additional serogroups can be expected in the future. Staining of the specimen with fluoresceinated pre-immune serum from the same animal as that from which the DFA antibody was obtained is required as a control to minimize the risk of falsely positive examinations. Unrelated bacteria that stain specifically with DFA reagents for L. pneumophila are infrequently encountered (175, 176).

Edelstein et al. reported that sputum specimens gave a higher yield than did transtracheal aspirates. Two bronchial washings and one transbronchial biopsy were even less satisfactory. In some instances the morphology of the DFA-staining bacteria became atypical after the patients began receiving antibiotics (140). Prior erythromycin therapy apparently reduces the sensitivity of DFA in postmortem diagnosis (124).

Serology

Indirect Immunofluorescence

The most widely used assay of antibody in convalescent serum specimens is the IFA (indirect fluorescent antibody) test (20, 178, 179). Fluoresceinated anti-human immunoglobulin is used as the conjugate, so the test detects IgG, IgM, and IgA (180). Since the antigen used in the test is whole heat-killed L. pneumophila cells, which presumably expose multiple determinants to the test serum, there is opportunity for cross-reaction with antibody to heterologous serogroups of L. pneumophila, other species of Legionella, and even completely unrelated bacteria.

Thirty-one (84%) of 37 Pontiac fever patients demonstrated seroconversion to L. pneumophila serogroup 1 (10) as did 90.9% of 111 patients from the 1976 Legionnaires' outbreak (20).

Nine (41%) of 22 patients with seroconversion by IFA reported by Edelstein et al. did not show a rise in titer to serogroup I antigen (140).

Most patients in whom seroconversion to L. pneumophila occurs have diagnostic titer elevations within three weeks of onset of illness. The optimal time to draw the convalescent-phase serum specimen is 14 to 60 days after onset (Table 15). Although a single IFA titer of 256 is sometimes taken as sufficient to establish that a recent illness represents infection with L. pneumophila (20), serodiagnosis from standing titers is hazardous, particularly if data are not available on the background prevalence of antibody in the referral population from which the patient comes.

Table 15. Time Required for Seroconversion in Serologically Proven Cases
Proportion (%) exhibiting IFA titer of at least 128

Week of illness:

1	12	13
2	48	55
3	82	84
4	90	94
5	94	98
6-10	89	100
Number of patients	101	31
Reference	20	124

Administration of pharmacologic doses of glucocorticoids does not appear to retard the antibody response in those who show seroconversion (124).

Microagglutination

A microagglutination test has been described (181). It chiefly detects IgM antibody (182).

Complement Fixation

L. pneumophila appears to fix complement poorly (166), a phenomenon that may have contributed to the failure to appreciate the significance of Jackson's original isolate (1).

Other Serologic Tests

Immune adherence hemagglutination, indirect hemagglutination (183), ELISA (184), and immunodiffusion (185) for antibody have all been described but are not widely used at present. Some serogroup cross-reactivity is seen with the indirect hemagglutination test. Differentiation between species and group-specific reactivity can be achieved by adsorption of sera with group-specific antigen (186).

Combined Modalities

The prolonged outbreak of nosocomial Legionnaires' disease at the Veterans Administration Wadsworth Medical Center in Los Angeles permitted an evaluation of available methods for the diagnosis of legionellosis in a uniform setting. The diagnosis was confirmed in 32 patients studied from October 1978 to May 1979. Direct immunofluorescence examination of respiratory tract secretions and indirect immunofluorescence assay of serum antibody detected 62% and 75%, respectively, of 13 culture-positive cases. When a positive result with any of the three techniques was taken as the definition of a case, IFA serologic tests (serogroups 1-4) were 81% sensitive (22/27), culture on charcoal yeast-extract agar was 62% sensitive (13/21), and direct immunofluorescence of respiratory tract secretions was 47% sensitive (15/32). The use of all three techniques in conjunction was recommended for optimal results (140).

Therapy

No controlled trials of therapy in humans have been reported. The available data come from series of patients treated with various combinations of antimicrobials at the discretion of the responsible physicians.

In the 1976 Legionnaires' outbreak the case-fatality rates were worst for patients treated with cephalosporins (41%), intermediate for those receiving aminoglycosidic aminocyclitols (36%), chloramphenicol (30%), ampicillin (24%), or penicillin G (20%), and best for those receiving erythromycin (11%) or tetracycline (10%) (135).

Beatty et al. reported case-fatality rates of 50% for untreated patients. The case-fatality rates were 32% in those receiving gentamicin, 26% with penicillin G, 25% with a cephalosporin, and 6% with erythromycin (86).

Kirby et al. reported a 13% case-fatality rate in 46 patients who received erythromycin, including 7% fatalities in 29 patients without immunosuppression and 24% fatalities in 17 immunosuppressed patients. In contrast, there was a 55% case-fatality rate in 18 patients who received no erythromycin (25% of eight patients without immunosuppression and 80% of ten immunosuppressed patients). In nine of the ten fatalities in patients not receiving erythromycin, death occurred within four to 13 days (mean 6 days) of onset. Subjective improvement was noted from 12 to 96 hours after initiation of oral or intravenous erythromycin with defervescence complete in a mean of 4.2 days (range 1-15). Kirby et al. recommended a dose of 2-4 g/day for a total of three weeks to avoid relapse or protracted convalescence (124).

Seven patients developed Legionnaires' disease while receiving ampicillin (two patients), penicillin, cefazolin, cephalixin, cephalirin, or tetracycline. Legionnaires' disease progressed in most patients given ampicillin, carbenicillin, oxacillin, penicillin, cefazolin, cephalixin, cephalothin, cefoxitin, amikacin, gentamicin, vancomycin, or clindamycin instead of erythromycin. A possible response was seen in two of four patients receiving tetracycline and in two patients given trimethoprim-sulfamethoxazole (124).

Horwitz and Silverstein have found that growth of L. pneumophila in human monocytes in vitro is rapidly but reversibly inhibited by concentrations of erythromycin or rifampin comparable to those that inhibit multiplication of the organism in BYE broth. However neither antimicrobial in concentrations equal to or greater than attainable peak serum levels effectively kills L. pneumophila that are multiplying within monocytes or suspended extracellularly in medium that does not support multiplication of these organisms (187).

Control Measures

Detection of Legionella in the Inanimate Environment

Environmental specimens can be screened for L. pneumophila using direct immunofluorescence (188). Passage of environmental specimens through guinea pigs and embryonated eggs has been used successfully to isolate L. pneumophila in the presence of large numbers of other microorganisms (189). Enrichment steps using low pH (190) or heat (191) have also been employed as an alternative to these biologic filters. Recent improvements in selective media for L. pneumophila permit isolation from potable water specimens after direct plating onto agar medium (33).

Decontamination

Decontamination of cooling towers has been attempted using chlorination at neutral pH with the goal of achieving a free chlorine residual of 100-250 ppm (119). Periodic flushing of the potable water system of a building with superheated water may be the best way of dealing with contamination of storage tanks, pipes, and outlets (95).

Non-pneumophila Legionellaceae

The development of CYE agar and its modifications and the search for L. pneumophila in environmental specimens has led to the discovery of the existence of many other gram-negative aerobic nonfermentative rods that do not grow on conventional bacteriologic media and that are characterized by a high proportion of branched-chain fatty acids. Most are known to have fresh-water aquatic habitats, and at least many are proven etiologic agents of pneumonia in man. These organisms have been classified together as members of the family Legionellaceae on the basis of their phenotypic similarities (192). Since these organisms share little to no homologous sequences as determined by hybridization of intact chromosomal DNA, they represent distinct species. Some workers have chosen to emphasize this lack of genetic relatedness by proposing new genera, Fluoribacter and Tatlockia, for some of these species, but despite assertions to the contrary (193) these designations do not have priority. Since their introduction offers no real advantage while complicating the terminology of workers in microbiology, clinical infectious disease, and public health, these alternate generic terms should be avoided (194).

Legionella micdadei

In the early 1940's outbreaks of an acute febrile illness characterized by an exanthem over the anterior aspect of the legs were reported from Wrens, Georgia (195), and Fort Bragg, North Carolina (196). The etiologic agent of Fort Bragg fever was ultimately isolated by Tatlock (197, 198) and subsequently shown to be a strain of the Autumnalis serogroup of Leptospira interrogans (199).

Early in the course of his investigations in North Carolina, Tatlock isolated a different microorganism from guinea pigs inoculated with blood from a case of Fort Bragg fever (200). This agent, a poorly staining gram-negative pleomorphic bacillus, was pathogenic for guinea pigs and could be maintained by passage in yolk sacs of fertile hens' eggs. No complement-fixing or agglutinating antibody to the agent was found in convalescent sera of patient who had had Fort Bragg fever, and the organism was presumed to be enzootic in the guinea pigs used in the laboratory (198, 200). Jackson reported antigenic differences between the Tatlock agent and the organism that she isolated in 1947, which was ultimately shown to be L. pneumophila (1).

In 1959 Marilyn Bozeman and her colleagues recovered an organism, designated Heba, from the spleen of a guinea pig inoculated with blood from a patient with suspected pityriasis rosea. The organism was pathogenic for guinea pigs and could be propagated in yolk sacs. It did not grow on any of a variety of bacteriologic media. Heba was found to be antigenically related to the Tatlock agent. Complement-fixing antibody to these agents was not detected in sera from humans and from thirteen genera of small mammals. Heba was presumed to have been latent in the guinea pig from which it had been isolated (101).

In 1979 Pasculle and his colleagues described an apparently newly recognized bacterium responsible for pneumonia in patients receiving

glucocorticoids or other immunosuppressive medications. A peripheral, pleurally based nodular or spherical infiltrate was felt to be radiographically typical (201). This organism and one described in immunocompromised patients in Charlottesville (202) have been shown to represent the same species as the Tatlock and Heba organisms. These have been given the designation Legionella micdadei (Pittsburgh pneumonia agent, L. pittsburgensis, Tatlockia micdadei) (203-205). Tatlock himself has recently emphasized that the evidence for a leptospiral etiology of Fort Bragg fever is substantial and that the agent that he isolated in 1943 was in all likelihood a contaminant in his cultures (198). Like L. pneumophila, L. micdadei has an aquatic habitat and has been isolated from respiratory therapy equipment (206) and potable water systems (207).

When tested on BCYE agar, L. micdadei is highly susceptible to erythromycin, rosaramycin, rifampin, chloramphenicol, and the penicillins, susceptible to cephalosporins, cefoxitin, moxalactam, and aminoglycosidic aminocyclitols, and resistant to clindamycin and vancomycin. No β -lactamase is produced (107). L. micdadei is also susceptible in vitro to other macrolide antibiotics (106).

Despite apparent differences in their efficacy in clinical infections, erythromycin, rifampin, penicillin G, cephalothin, and gentamicin are bactericidal against L. micdadei in vitro. Mutants resistant to rifampin can be selected by exposure to low doses of this agent (208).

Clinical experience indicates that β -lactam antibiotics are inefficacious and that erythromycin is the drug of choice in infections with L. micdadei (209). Respiratory secretions may be positive by culture or DFA for days after institution of erythromycin therapy (144).

Legionella bozemanii

In 1958 a 38-year-old Navy SCUBA diver died after developing fulminant bronchopneumonia while in training (210). In January 1959 Marilyn Bozeman and her colleagues at the Walter Reed Army Institute of Research recovered an organism, designated Wiga, from the brain of a guinea pig inoculated with lung tissue from the dead man. The organism was pathogenic for guinea pigs and could be propagated in yolk sacs. It did not grow on any of a variety of bacteriologic media. Wiga was found to share an antigenic determinant common to Olda, Tatlock, and Heba. It was resistant to penicillin G in ovo. Complement-fixing antibodies were not detected in sera from humans and 13 genera of small mammals. As with the other "rickettsia-like agents," it was considered to have been latent in the guinea pig from which it had been isolated (101).

An identical organism was isolated from the lung of a patient with chronic lymphocytic leukemia who developed a fatal case of pneumonia after a boating accident in a brackish swamp (210). This organism has been given the designation L. bozemanii (Fluoribacter bozemaniae) (211).

Although L. bozemanii does produce β -lactamase, its antimicrobial susceptibility pattern in vitro on BCYE agar resembles that of L. micdadei (107). L. bozemanii is susceptible to a variety of macrolides (106).

Legionella dumoffii

During investigations of an outbreak of infection with L. pneumophila in the garment district of New York (117), a similar but distinct organism was isolated from a cooling tower (210). This isolate, is the type strain of the species designated L. dumoffii (211).

An isolate of L. dumoffii has been recovered from the lung of a man with small-cell carcinoma of the lung who died of pneumonia in Houston (212). This organism has also been recognized by DFA in a specimen of lung from a woman in San Antonio who developed fatal pneumonia while receiving glucocorticoid therapy for systemic lupus erythematosus (213).

L. dumoffii has β -lactamase activity. Its antibiotic susceptibility pattern in vitro on BCYE agar resembles that of L. pneumophila (107). L. dumoffii is susceptible in vitro to a variety of macrolide antibiotics (106).

Legionella gormanii

The fifth species of Legionella to be described was L. gormanii (214). The type strain was recovered from soil collected from a creek bank at a country club in Atlanta that was the site of an outbreak of disease caused by L. pneumophila (84). The organism has been recognized by DFA in the lung of a man in Connecticut who died of pneumonia (214).

Although L. gormanii does produce β -lactamase, it has an antimicrobial susceptibility pattern in vitro on BCYE agar similar to that of L. micdadei (107).

Legionella longbeachae

Four cases of pneumonia in both previously healthy and immunosuppressed patients that were associated with recovery of a new species of Legionella from respiratory secretions were reported in 1981. The organism has been designated L. longbeachae. Evidence of clinical benefit of treatment with erythromycin with or without rifampin was seen in three of the four (215). A fatal case of pneumonia with a strain L. longbeachae belonging to a distinct second serogroup of this species has been reported (216).

L. longbeachae is susceptible in vitro to various macrolide antibiotics (106).

Legionella jordanis

Two isolates from specimens of fresh water have been classified as belonging to a species designated L. jordanis (217), named after the Jordan River on the campus of Indiana University, where the first of these was recovered during the investigation of an outbreak of infection with L. pneumophila (83). Serologic evidence suggests a role for this organism in cases of pneumonia in man (179, 217).

Legionella wadsworthii

L. wadsworthii is represented by an isolate recovered from the sputum of a patient with pneumonia and underlying chronic lymphocytic leukemia who was admitted to the Veterans Administration Wadsworth Medical Center in November 1981. The patient responded slowly to antimicrobial therapy that included erythromycin and rifampin (218).

Legionella oakridgensis

The most recently named species of Legionella is L. oakridgensis, which is represented by ten strains isolated from industrial cooling towers. These organisms produce illness in experimentally infected guinea pigs but have yet to be associated with human disease (219).

W0-44

A Legionella-like organism represented by the isolate W0-44 has been shown to be responsible for an outbreak of illness resembling Pontiac fever that affected 395 engine assembly plant workers at a factory in Windsor, Ontario, in August 1981. Epidemiologic studies suggested airborne transmission from the coolant system in the piston department (220).

References

1. Jackson EB, Crocker TT, Smadel JE. Studies on two rickettsia-like agents probably isolated from guinea pigs. *Bacteriological Proceedings*. Baltimore: The Society of American Bacteriologists, 1952:119.
2. McDade JE, Brenner DJ, Bozeman FM. Legionnaires' disease bacterium isolated in 1947. *Ann Intern Med* 1979;90:659-61.
3. Bozeman FM. Personal communication, 15 February 1983.
4. National Office of Vital Statistics. Pneumonia. Morbidity and Mortality Weekly Report 1957;6(31):2.
5. Osterholm MT, Chin TDY, Osborne DO, Dull HB, Dean AG, Fraser DW, Hayes PS, Hall WN. A 1957 outbreak of Legionnaires' disease associated with a meat packing plant. *Am J Epidemiol* 1983;117:60-7.
6. Communicable Disease Center. Institutional outbreak of pneumonia-- Washington, D.C. Morbidity and Mortality Weekly Report 1965;14:265-6.
7. Thacker SB, Bennett JV, Tsai TF, Fraser DW, McDade JE, Shepard CC, Williams KH Jr, Stuart WH, Dull HB, Eickhoff TC. An outbreak in 1965 of severe respiratory illness caused by the Legionnaires' disease bacterium. *J Infect Dis* 1978;138:512-9.
8. National Communicable Disease Center. Epidemic of obscure illness. Morbidity and Mortality Weekly Report 1968;17:315, 320.
9. Glick TH, Gregg MB, Berman B, Mallison G, Rhodes WW Jr, Kassanoff I. Pontiac fever. An epidemic of unknown etiology in a health department: I. Clinical and epidemiologic aspects. *Am J Epidemiol* 1978;107:149-60.
10. Kaufmann AF, McDade JE, Patton CM, Bennett JV, Skaliy P, Feeley JC, Anderson DC, Potter ME, Newhouse VF, Gregg MB, Brachman PS. Pontiac fever: isolation of the etiologic agent (Legionella pneumophila) and demonstration of its mode of transmission. *Am J Epidemiol* 1981;114:337-47.
11. Reid D, Grist NR, Najera R. Illness associated with "package tours": a combined Spanish-Scottish study. *Bull Wld Hlth Org* 1978;56:117-22.
12. Lawson JH. Legionnaires' disease--the Benidorm episode. *Scot Med J* 1978;23:212-4.
13. Grist NR, Reid D, Najera R. Legionnaires' disease and the traveller. *Ann Intern Med* 1979;90:563-4.
14. Deubner DC, Gilliam DK. Fever of undetermined etiology after cleaning of steam condensers. *Arch Environ Health* 1977;32:116-9.
15. Fraser DW, Deubner DC, Hill DL, Gilliam DK. Nonpneumonic, short-incubation-period legionellosis (Pontiac fever) in men who cleaned a steam turbine condenser. *Science* 1979;205:690-1.

16. Terranova W, Cohen ML, Fraser DW. 1974 outbreak of Legionnaires' disease diagnosed in 1977. Clinical and epidemiological features. *Lancet* 1978;2:122-4.
17. Fraser DW, Tsai TF, Orenstein W, Parkin WE, Beecham HJ, Sharrar RG, Harris J, Mallison GF, Martin SM, McDade JE, Shepard CC, Brachman PS, Field Investigation Team. Legionnaires' disease. Description of an epidemic of pneumonia. *N Engl J Med* 1977;297:1189-97.
18. Dumoff M. Direct in-vitro isolation of the Legionnaires' disease bacterium in two fatal cases. Cultural and staining characteristics. *Ann Intern Med* 1979;90:694-6.
19. McDade JE. Personal communication, 11 February 1983.
20. McDade JE, Shepard CC, Fraser DW, Tsai TF, Redus MA, Dowdle WR, Laboratory Investigation Team. Legionnaires disease. Isolation of a bacterium and demonstration of its role in other respiratory disease. *N Engl J Med* 1977;297:1218-20.
21. Brenner DJ, Steigerwalt AG, McDade JE. Classification of the Legionnaires' disease bacterium: Legionella pneumophila, genus novum, species nova, of the family Legionellaceae, familia nova. *Ann Intern Med* 1979;90:656-8.
22. Feeley JC, Gorman GW. Legionella. In: Lennette EH, Balows A, Hausler WJ Jr, Truant JP, eds. *Manual of clinical microbiology*. 3rd ed. Washington: American Society for Microbiology, 1980:318-24.
23. Feeley JC, Gorman GW, Weaver RE, Mackel DC, Smith HW. Primary isolation media for Legionnaires' disease bacterium. *J Clin Microbiol* 1978; 8:320-5.
24. Thornsberry C, Gavan TL, Gerlach EH. New developments in antimicrobial agent susceptibility testing. In: Sherris JC, ed. *Cumitech 6*. Washington: American Society for Microbiology, 1977:1-13.
25. Feeley JC, Gibson RJ, Gorman GW, Langford NC, Rasheed JK, Mackel DC, Baine WB. Charcoal-yeast extract agar: primary isolation medium for Legionella pneumophila. *J Clin Microbiol* 1979;10:437-41.
26. Pasculle AW, Feeley JC, Gibson RJ, Cordes LG, Myerowitz RL, Patton CM, Gorman GW, Carmack CL, Ezzell JW, Dowling JN. Pittsburgh pneumonia agent: direct isolation from human lung tissue. *J Infect Dis* 1980; 141:727-32.
27. Edelstein PH. Improved semiselective medium for isolation of Legionella pneumophila from contaminated clinical and environmental specimens. *J Clin Microbiol* 1981;14:298-303.
28. Muller D, Edwards ML, Smith DW. Changes in iron and transferrin levels and body temperature in experimental airborne legionellosis. *J Infect Dis* 1983;147:302-7.

29. Vickers RM, Brown A, Garrity GM. Dye-containing buffered charcoal-yeast extract medium for differentiation of members of the family Legionellaceae. J Clin Microbiol 1981;13:380-2.
30. Holmes RL. Aniline blue-containing buffered charcoal-yeast extract medium for presumptive identification of Legionella species. J Clin Microbiol 1982;15:723-4.
31. Edelstein PH, Finegold SM. Use of a semiselective medium to culture Legionella pneumophila from contaminated lung specimens. J Clin Microbiol 1979;10:141-3.
32. Wadowsky RM, Yee RB. A glycine-containing selective medium for isolation of Legionellaceae from environmental specimens. Appl Environ Microbiol 1981;42:768-72.
33. Edelstein PH. Comparative study of selective media for isolation of Legionella pneumophila from potable water. J Clin Microbiol 1982;16:697-9.
34. Weaver RE, Feeley JC. Cultural and biochemical characterization of the Legionnaires' disease bacterium. In: Jones GL, Hebert GA, eds. "Legionnaires'." The disease, the bacterium and methodology. Atlanta: Center for Disease Control, 1979:20-5.
35. Gimenez DF. Staining rickettsiae in yolk-sac cultures. Stain Technol 1964;39:135-40.
36. Thomason BM, Chandler FW, Hollis DG. Flagella on Legionnaires' disease bacteria: an interim report. Ann Intern Med 1979;91:224-6.
37. West M, Burdash NM, Freimuth F. Simplified silver-plating stain for flagella. J Clin Microbiol 1977;6:414-9.
38. Clark WA. A simplified Leifson flagella stain. J Clin Microbiol 1976;3:632-4.
39. Chandler FW, Thomason BM, Hebert GA. Flagella on Legionnaires' disease bacteria in the human lung. Ann Intern Med 1980;93:715-6.
40. Flesher AR, Ito S, Mansheim BJ, Kasper DL. The cell envelope of the Legionnaires' disease bacterium. Ann Intern Med 1979;90:628-30.
41. Chandler FW, Cole RM, Hicklin MD, Blackmon JA, Callaway CS. Ultrastructure of the Legionnaires' disease bacterium. A study using transmission electron microscopy. Ann Intern med 1979;90:642-7.
42. Neblett TR, Riddle JM, Dumoff M. Surface topography and fine structure of the Legionnaires' disease bacterium. A study of six isolates from hospitalized patients. Ann Intern Med 1979;90:648-51.
43. Keel JA, Finnerty WR, Feeley JC. Fine structure of the Legionnaires' disease bacterium. In-vitro and in-vivo studies of four isolates. Ann Intern Med 1979;90:652-5.

44. Guerrant GO, Lambert MS, Moss CW. Identification of diaminopimelic acid in the Legionnaires disease bacterium. *J Clin Microbiol* 1979;10:815-8.
45. Rodgers FG, Greaves PW, Macrae AD. Flagella and fimbriae on Legionella organisms. *Lancet* 1979;2:753-4.
46. Chandler FW, Roth IL, Callaway CS, Bump JL, Thomason BM, Weaver RE. Flagella on Legionnaires' disease bacteria: ultrastructural observations. *Ann Intern Med* 1980;93:711-4.
47. Katz SM, Nash P. Legionnaires' disease: structural characteristics of the organism. *Science* 1978;199:896-7.
48. Katz SM, Nash P. The morphology of the Legionnaires' disease organism. *Am J Pathol* 1978;90:701-22.
49. McKinney RM, Thacker L, Harris PP, Lewallen KR, Hebert GA, Edelstein PH, Thomason BM. Four serogroups of Legionnaires' disease bacteria defined by direct immunofluorescence. *Ann Intern Med* 1979;90:621-4.
50. Wong KH, Schalla WO, Arko RJ, Bullard JC, Feeley JC. Immunochemical, serologic, and immunologic properties of major antigens isolated from the Legionnaires' disease bacterium. *Ann Intern Med* 1979;90:634-8.
51. Johnson W, Elliott JA, Helms CM, Renner ED. A high molecular weight antigen in Legionnaires' disease bacterium: isolation and partial characterization. *Ann Intern Med* 1979;90:638-41.
52. Flesher AR, Jennings HJ, Lugowski C, Kasper DL. Isolation of a serogroup 1-specific antigen from Legionella pneumophila. *J Infect Dis* 1982;145:224-33.
53. Joly JR, Kenny GE. Antigenic analysis of Legionella pneumophila and Tatlockia micdadei (Legionella micdadei) by two-dimensional (crossed) immunoelectrophoresis. *Infect Immun* 1982;35:721-9.
54. Smith RA, DiGiorgio S, Darner J, Wilhelm A. Detection of Legionella pneumophila capsular-like envelope antigens by counterimmunoelectrophoresis. *J Clin Microbiol* 1981;13:637-42.
55. Elliott JA, Johnson W. Immunological and biochemical relationships among flagella isolated from Legionella pneumophila serogroups 1, 2, and 3. *Infect Immun* 1981;33:602-10.
56. Moss CW, Weaver RE, Dees SB, Cherry WB. Cellular fatty acid composition of isolates from Legionnaires' disease. *J Clin Microbiol* 1977;6:140-3.
57. Moss CW, Dees SB. Further studies of the cellular fatty acid composition of Legionnaires disease bacteria. *J Clin Microbio* 1979;9:648-9.
58. Mayberry WR. Dihydroxy and monohydroxy fatty acids in Legionella pneumophila. *J Bacteriol* 1981;147:373-81.

59. Finnerty WR, Makula RA, Feeley JC. Cellular lipids of the Legionnaires' disease bacterium. *Ann Intern Med* 1979;90:631-4.
60. Weiss E, Peacock MG, Williams JC. Glucose and glutamate metabolism of Legionella pneumophila. *Current Microbiology* 1980;4:1-6.
61. Hebert GA. Hippurate hydrolysis by Legionella pneumophila. *J Clin Microbiol* 1981;13:240-2.
62. Pine L, George JR, Reeves MW, Harrell WK. Physiology: characteristics of the Legionnaires' disease bacterium in semisynthetic and chemically defined liquid media. In: Jones GL, Hebert GA, eds. "Legionnaires'." The disease, the bacterium and methodology. Atlanta: Center for Disease Control, 1979:27-40.
63. Pine L, George JR, Reeves MW, Harrell WK. Development of a chemically defined liquid medium of Legionella pneumophila. *J Clin Microbiol* 1979;9:615-26.
64. Warren WJ, Miller RD. Growth of Legionnaires disease bacterium (Legionella pneumophila) in chemically defined medium. *J Clin Microbiol* 1979;10:50-5.
65. George JR, Pine L, Reeves MW, Harrell WK. Amino acid requirements of Legionella pneumophila. *J Clin Microbiol* 1980;11286-91.
66. Tesh MJ, Miller RD. Amino acid requirements for Legionella pneumophila growth. *J Clin Microbiol* 1981;13:865-9.
67. Baine WB, Rasheed JK, Feeley JC, Gorman GW, Casida LE Jr. Effect of supplemental L-tyrosine on pigment production in cultures of the Legionnaires' disease bacterium. *Current Microbiology* 1978;1:93-4.
68. Baine WB, Rasheed JK. Aromatic substrate specificity of browning by cultures of the Legionnaires' disease bacterium. *Ann Intern Med* 1979;90:619-20.
69. Baine WB, Rasheed JK, Mackel DC, Bopp CA, Wells JG, Kaufmann AF. Exotoxin activity associated with the Legionnaires' disease bacterium. *J Clin Microbiol* 1979;9:453-6.
70. Muller HE. Enzymatic profile of Legionella pneumophila. *J Clin Microbiol* 1981;13:423-6.
71. Nolte FS, Hollick GE, Robertson RG. Enzymatic activities of Legionella pneumophila and Legionella-like organisms. *J Clin Microbiol* 1982;15:175-7.
72. Thorpe TC, Miller RD. Extracellular enzymes of Legionella pneumophila. *Infect Immun* 1981;33:632-5.
73. Muller HE. Proteolytic action of Legionella pneumophila on human serum proteins. *Infect Immun* 1980;27:51-3.

74. Thompson MR, Miller RD, Iglewski BH. In vitro production of an extracellular protease by Legionella pneumophila. *Infect Immun* 1981; 34:299-302.
75. Berdal BP, Fossum K. Occurrence and immunogenicity of proteinases from Legionella species. *European Journal of Clinical Microbiology* 1982; 1:7-11.
76. Brenner DJ, Steigerwalt AG, Weaver RE, McDade JE, Feeley JC, Mandel M. Classification of the Legionnaires' disease bacterium: an interim report. *Current Microbiology* 1978;1:71-5.
77. Knudson GB, Mikesell P. A plasmid in Legionella pneumophila. *Infect Immun* 1980;29:1092-5.
78. Aye T, Wachsmuth K, Feeley JC, Gibson RJ, Johnson SR. Plasmid profiles of Legionella species. *Current Microbiology* 1981;6:389-94.
79. Mikesell P, Ezzell JW, Knudson GB. Isolation of plasmids in Legionella pneumophila and Legionella-like organisms. *Infect Immun* 1981;31:1270-2.
80. Brown A, Vickers RM, Elder EM, Lema M, Garrity GM. Plasmid and surface antigen markers of endemic and epidemic Legionella pneumophila strains. *J Clin Microbiol* 1982;16:230-5.
81. Fliermans CB, Cherry WB, Orrison LH, Thacker L. Isolation of Legionella pneumophila from non-epidemic-related aquatic habitats. *Appl Environ Microbiol* 1979;37:1239-42.
82. Fliermans CB, Cherry WB, Tison DL, Smith RB, Pope DH. Ecological niche of Legionella pneumophila. *Appl Environ Microbiol* 1981;41:9-16.
83. Politi BD, Fraser DW, Mallison GF, Mohatt JV, Morris GK, Patton CM, Feeley JC, Telle RD, Bennett JV. A major focus of Legionnaires' disease in Bloomington, Indiana. *Ann Intern Med* 1979;90:587-91.
84. Cordes LG, Fraser DW, Skaliy P, Perlino CA, Elsea WR, Mallison GF, Hayes PS. Legionnaires' disease outbreak at an Atlanta, Georgia, country club: evidence for spread from an evaporative condenser. *Am J Epidemiol* 1980;111:425-31.
85. Marks JS, Tsai TF, Martone WJ, Baron RC, Kennicott J, Holtzhauer FJ, Baird I, Fay D, Feeley JC, Mallison GF, Fraser DW, Halpin TJ. Nosocomial legionnaires' disease in Columbus, Ohio. *Ann Intern Med* 1979;90:565-9.
86. Beaty HN, Miller AA, Broome CV, Goings S, Phillips CA. Legionnaires' disease in Vermont, May to October 1977. *JAMA* 240:127-31.
87. Broome CV, Goings SAJ, Thacker SB, Vogt RL, Beaty HN, Fraser DW, Field Investigation Team. The Vermont epidemic of Legionnaires' disease. *Ann Intern Med* 1979;90:573-6.

88. Broome CV, Fraser DW. Epidemiologic aspects of legionellosis. *Epidemiol Rev* 1979;1:1-16.
89. Dondero TJ Jr, Clegg HW II, Tsai TF, Weeks RM, Duncan E, Strickler J, Chapman C, Mallison GF, Politi B, Potter ME, Schaffner W. Legionnaires' disease in Kingsport, Tennessee. *Ann Intern Med* 1979;90:569-73.
90. Dondero TJ Jr, Rendtorff RC, Mallison GF, Weeks RM, Levy JS, Wong EW, Schaffner W. An outbreak of legionnaires' disease associated with a contaminated air-conditioning cooler tower. *N Engl J Med* 1980;302:365-70.
91. Band JD, LaVenture M, Davis JP, Mallison GF, Skaliy P, Hayes PS, Schell WL, Weiss H, Greenberg DJ, Fraser DW. Epidemic Legionnaires' disease. Airborne transmission down a chimney. *JAMA* 1981;245:2404-7.
92. Fisher-Hoch SP, Bartlett CLR, Tobin J O'H, Gillett MB, Nelson AM, Pritchard JE, Smith MG, Swann RA, Talbot JM, Thomas JA. Investigation and control of an outbreak of Legionnaires' disease in a district general hospital. *Lancet* 1981;1:932-6.
93. Conwill DE, Werner SB, Dritz SK, Bissett M, Coffery E, Nygaard G, Bradford L, Morrison FR, Knight MW. Legionellosis--the 1980 San Francisco outbreak. *Am Rev Respir Dis* 1982;126:666-9.
94. Tobin J O'H, Beare J, Dunnill MS, Fisher-Hoch S, French M, Mitchell RG, Morris PJ, Muers MF. Legionnaires' disease in a transplant unit: isolation of the causative agent from shower baths. *Lancet* 1980;2:118-21.
95. Cordes LG, Wiesenthal AM, Gorman GW, Phair JP, Sommers HM, Brown A, Yu VL, Magnuson MH, Meyer RD, Wolf JS, Shands KN, Fraser DW. Isolation of Legionella pneumophila from hospital shower heads. *Ann Intern Med* 1981;94:195-7.
96. Arnow PM, Chou T, Weil D, Shapiro EN, Kretzschmar C. Nosocomial legionnaires' disease caused by aerosolized tap water from respiratory devices. *J Infect Dis* 1982;146:460-7.
97. Stout J, Yu VL, Vickers RM, Zuravleff J, Best M, Brown A, Yee RB, Wadowsky R. Ubiquitousness of Legionella pneumophila in the water supply of a hospital with endemic Legionnaires' disease. *N Engl J Med* 1982;306:466-8.
98. Rosmini F, Castellani Pastoris M, Mazzotti MF, Forastiere F, Gavazzoni A, Greco D, Ruckdeschel G, Tartagni E, Zampieri A, Baine WB. Legionellosis in successive cohorts of tourists at a hotel on the Italian Adriatic coast. In press.
99. Tison DL, Pope DH, Cherry WB, Fliermans CB. Growth of Legionella pneumophila in association with bluegreen algae (cyanobacteria). *Appl Environ Microbiol* 1980;39:456-9.

100. Berendt RF. Influence of blue-green algae (cyanobacteria) on survival of Legionella pneumophila in aerosols. *Infect Immun* 1981;32:690-2.
101. Bozeman FM, Humphries JW, Campbell JM. A new group of rickettsia-like agents recovered from guinea pigs. *Acta Virol (Praha)* 1968;12:87-93.
102. Thornsberry C, Kirven LA. β -Lactamase of the Legionnaires' bacterium. *Current Microbiology* 1978;1:51-4.
103. Fu KP, Neu HC. Inactivation of β -lactam antibiotics by Legionella pneumophila. *Antimicrob Agents Chemother* 1979;16:561-4.
104. Thornsberry C, Baker CN, Kirven LA. In vitro activity of antimicrobial agents on Legionnaires disease bacterium. *Antimicrob Agents Chemother* 1978;12:78-80.
105. Edelstein PH, Meyer RD. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. *Antimicrob Agents Chemother* 1980;18:403-8.
106. Edelstein PH, Pasiiecznik KA, Yasui VK, Meyer RD. Susceptibility of Legionella spp. to minamycin I and II and other macrolide antibiotics: effects of media composition and origin of organisms. *Antimicrob Agents Chemother* 1982;22:90-3.
107. Pasculle AW, Dowling JN, Weyant RS, Sniffen JM, Cordes LG, Gorman GW, Feeley JC. Susceptibility of Pittsburgh pneumonia agent (Legionella micdadei) and other newly recognized members of the genus Legionella to nineteen antimicrobial agents. *Antimicrob Agents Chemother* 1981;20:793-9.
108. Bacheson MA, Friedman HM, Benson CE. Antimicrobial susceptibility of intracellular Legionella pneumophila. *Antimicrob Agents Chemother* 1981;20:691-2.
109. Lewis VJ, Thacker WL, Shepard CC, McDade JE. In vivo susceptibility of the Legionnaires disease bacterium to ten antimicrobial agents. *Antimicrob Agents Chemother* 1978;13:419-22.
110. Fraser DW, Wachsmuth IK, Bopp C, Feeley JC, Tsai TF. Antibiotic treatment of guineapigs infected with agent of Legionnaires' disease. *Lancet* 1978;1:175-8.
111. Yonke CA, Stiefel HE, Wentworth BB, Wilson DL. Prevalence of antibody to serogroups 1-4 of Legionella pneumophila: a seroepidemiologic study using the indirect hemagglutination test. *Am J Epidemiol* 1982;115:633-9.
112. Macrae AD, Appleton PN, Laverick A. Legionnaires' disease in Nottingham, England. *Ann Intern Med* 1979;90:573-7.
113. Storch G, Hayes PS, Hill DL, Baine WB. Prevalence of antibody to Legionella pneumophila in middle-aged and elderly Americans. *J Infect Dis* 1979;140:784-8.

114. Haley CE, Cohen ML, Halter J, Meyer RD. Nosocomial Legionnaires' disease: a continuing common source epidemic at Wadsworth Medical Center. *Ann Intern Med* 1979;90:583-6.
115. Freedman AP, Katz SM. The prevalence of serum antibodies to Legionella pneumophila in patients with chronic pulmonary disease. *Am Rev Respir Dis* 1981;123:238-9.
116. Storch G, Hayes PS, Meyers JD, Sulzer A, Baine WB. Legionnaires' disease bacterium: prevalence of antibody reacting with the organism in patients suspected of having infection with Pneumocystis carinii. *Am Rev Resp Dis* 1980;121:483-6.
117. Cordes LG, Goldman WD, Marr JS, Friedman SM, Band JD, Rothschild EO, Kravitz H, Feeley JC, Fraser DW, Field Investigation Team. Legionnaires' disease in New York City. *Bull NY Acad Med* 1980;56:467-82.
118. England AC, McKinney RM, Skaliy P, Gorman GW. A fifth serogroup of Legionella pneumophila. *Ann Intern Med* 1980;93:58-9.
119. Conwill DE, Werner SB, Dritz SK, Bissett M, Coffey E, Nygaard G, Bradford L, Morrison FR, Knight MW. Legionellosis--the 1980 San Francisco outbreak. *Am Rev Respir Dis* 1982;126:666-9.
120. Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. *Lancet* 1982;2:255-8.
121. Yu VL, Kroboth FJ, Shonnard J, Brown A, McDearman S, Magnussen M. Legionnaires' disease: new clinical perspective from a prospective pneumonia study. *Am J Med* 1982;73:357-61.
122. Bock BV, Kirby BD, Edelstein PH, George WL, Snyder KM, Owens ML, Hatayama CM, Haley CE, Lewis RP, Meyer RD, Finegold SM. Legionnaires' disease in renal-transplant recipients. *Lancet* 1978;1:410-13.
123. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: clinical features of 24 cases. *Ann Intern Med* 1978;89:297-309.
124. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases and review of the literature. *Medicine (Baltimore)* 1980;59:188-205.
125. Cohen ML, Broome CV, Paris AL, Martin WT, Allen JR. Fatal nosocomial Legionnaires' disease: clinical and epidemiologic characteristics. *Ann Intern Med* 1979;90:611-3.
126. Haley CE, Cohen ML, Halter J, Meyer RD. Nosocomial Legionnaires' disease: a continuing common-source epidemic at Wadsworth Medical Center. *Ann Intern Med* 1979;90:583-6.
127. England AC III, Fraser DW. Sporadic and epidemic nosocomial legionellosis in the United States. *Am J Med* 1981;70:707-11.

128. England AC III, Fraser DW, Plikaytis BD, Tsai TF, Storch G, Broome CV. Sporadic legionellosis in the United States: the first thousand cases. *Ann Intern Med* 1981;94:164-70.
129. Miller RP. Cooling towers and evaporative condensers. *Ann Intern Med* 1979;90:667-70.
130. Andersen RD, Lauer BA, Fraser DW, Hayes PS, McIntosh K. Infections with Legionella pneumophila in children. *J Infect Dis* 1981;143:386-90.
131. Orme RLF, Haas L, Cruickshank JG, Hart RJC, Anderson AW. Legionnaires' disease in infants. *Lancet* 1980;2:1027.
132. Storch G, Baine WB, Fraser DW, Broome CV, Clegg HW II, Cohen ML, Goings SAJ, Politi BD, Terranova WA, Tsai TF, Plikaytis BD, Shepard CC, Bennett JV. Sporadic community-acquired Legionnaires' disease in the United States. A case-control study. *Ann Intern Med* 1979;90:596-600.
133. Meenhorst PL, van der Meer JWM, Borst J. Sporadic cases of Legionnaires' disease in the Netherlands. *Ann Intern Med* 1979;90:529-32.
134. Snell JD Jr. Effects of inhaled endotoxin. *J Lab Clin Med* 1966;67:624-32.
135. Tsai TF, Finn DR, Plikaytis BD, McCauley W, Martin SM, Fraser DW. Legionnaires' disease: Clinical features of the epidemic in Philadelphia. *Ann Intern Med* 1979;90:509-17.
136. Miller AC. Early clinical differentiation between Legionnaires' disease and other sporadic pneumonias. *Ann Intern Med* 1979;90:526-8.
137. Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. *Ann Intern Med* 1979;90:543-7.
138. Sharrar RG, Friedman HM, Miller WT, Yanak MJ, Abrutyn E. Summertime pneumonias in Philadelphia in 1976. *Ann Intern Med* 1979;90:577-80.
139. Gregory DW, Schaffner W, Alford RH, Kaiser AB, McGee ZA. Sporadic cases of Legionnaires' disease: The expanding clinical spectrum. *Ann Intern Med* 1979;90:518-21.
140. Edelstein PH, Meyer RD, Finegold SM. Laboratory diagnosis of Legionnaires' disease. *Am Rev Respir Dis* 1980;122:317-27.
141. Storch GA, Sagel SS, Baine WB. The chest radiograph in sporadic cases of Legionnaires' disease. *JAMA* 1981;245:587-90.
142. Gump DW, Frank RO, Winn WC Jr, Foster RS Jr, Broome CV, Cherry WB. Legionnaires' disease in patients with associated serious disease. *Ann Intern Med* 1979;90:538-42.

143. Edelstein PH, Meyer RD, Finegold SM. Long-term followup of two patients with pulmonary cavitation caused by Legionella pneumophila. Am Rev Respir Dis 1981;124:90-3.
144. Dowling JN, Kroboth FJ, Karpf M, Yee RB, Pasculle AW. Pneumonia and multiple lung abscesses caused by dual infection with Legionella micdadei and Legionella pneumophila. Am Rev Respir Dis 1983;127:121-5.
145. Dorman SA, Hardin NJ, Winn WC Jr. Pyelonephritis associated with Legionella pneumophila, serogroup 4. Ann Intern Med 1980;93:835-7.
146. Dournon E, Bure A, Kemeny JL, Pourriat JL, Valeyre D. Legionella pneumophila peritonitis. Lancet 1982;1:1363.
147. Arnow PM, Boyko EJ, Friedman EL. Perirectal abscess caused by Legionella pneumophila and mixed anaerobic bacteria. Ann Intern Med 1983;98:184-5.
148. Kalweit WH, Winn WC Jr, Rocco TA Jr, Girod JC. Hemodialysis fistula infections caused by Legionella pneumophila. Ann Intern Med 1982;96:173-5.
149. Weisenburger DD, Rappaport H, Ahluwalia MS, Melvani R, Renner ED. Legionnaires' disease. Am J Med 1980;69:476-82.
150. Milder JE, Rough RR. Concurrent Legionnaires' disease and active pulmonary tuberculosis. Am Rev Respir Dis 1982;125:759-61.
151. Babich JE, Resnick A, Fink JN. Hypersensitivity pneumonitis and Legionnaires' disease. Am Rev Respir Dis 1980;121:885-7.
152. Blackmon JA, Hicklin MD, Chandler FW, Special Expert Pathology Panel. Legionnaires' disease. Pathological and historical aspects of a 'new' disease. Arch Pathol Lab Med 1978;102:337-43.
153. Winn WC Jr, Myerowitz RL. The pathology of the Legionella pneumonias. Hum Pathol 1981;12:401-22.
154. Chandler FW, Hicklin MD, Blackmon JA. Demonstration of the agent of Legionnaires' disease in tissue. N Engl J Med 1977;297:1218-20.
155. Van Orden AE, Greer PW. Modification of the Dieterle spirochete stain. J Histotechnol 1977;2:51-3.
156. Davis GS, Winn WC Jr, Gump DW, Craighead JE, Beaty HN. Legionnaires' pneumonia after aerosol exposure in guinea pigs and rats. Am Rev Respir Dis 1982;126:1050-7.
157. Highsmith AK, Mackel DC, Baine WB, Anderson RL, Fraser DW. Observations of endotoxin-like activity associated with the Legionnaires' disease bacterium. Current Microbiology 1978;1:315-7.

158. Wong KH, Moss CW, Hochstein DH, Arko RJ, Schalla WO. "Endotoxicity" of the Legionnaires' disease bacterium. *Ann Intern Med* 1979;90:624-7.
159. Miragliotta G, Semeraro N, Marcuccio L, Fumarola D. *Infection* 1982;in press.
160. Friedman RL, Iglewski BH, Miller RD. Identification of a cytotoxin produced by Legionella pneumophila. *Infect Immun* 1980;29:271-4.
161. Friedman RL, Lochner JE, Bigley RH, Iglewski BH. The effects of Legionella pneumophila toxin on oxidative processes and bacterial killing of human polymorphonuclear leukocytes. *J Infect Dis* 1982;146:328-34.
162. Baine WB, Rasheed JK, Maca HW, Kaufmann AF. Hemolytic activity of plasma and urine from rabbits experimentally infected with Legionella pneumophila. *Rev Infect Dis* 1979;1:912-7.
163. Baine WB. Cytolytic exotoxin and phospholipase C activity in Legionella species. *Clinical Research* 1983;31:in press.
164. Baine WB. Phenylalanine 4-monooxygenase and tyrosine 3-monooxygenase in Legionella species. In: American Society for Microbiology. Abstracts of the Annual Meeting of the American Society for Microbiology, 1983. Washington: American Society for Microbiology, 1983:in press.
165. Wilkinson HW, Farshy CE, Fikes BJ, Cruce DD, Yealy LP. Measure of immunoglobulin G-, M-, and A-specific titers against Legionella pneumophila and inhibition of titers against nonspecific, gram-negative bacterial antigens in the indirect immunofluorescence test for legionellosis. *J Clin Microbiol* 1979;10:685-9.
166. Horwitz MA, Silverstein SC. Interaction of the Legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. I. L. pneumophila resists killing by polymorphonuclear leukocytes, antibody, and complement. *J Exp Med* 1981;153:386-97.
167. Horwitz MA, Silverstein SC. Legionnaires' disease bacterium (Legionella pneumophila) multiplies intracellularly in human monocytes. *J Clin Invest* 1980;66:441-50.
168. Horwitz MA, Silverstein SC. Interaction of the Legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. II. Antibody promotes binding of L. pneumophila to monocytes but does not inhibit intracellular multiplication. *J Exp Med* 1981;153:398-406.
169. Horwitz MA, Silverstein SC. Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria. *J Exp Med* 1981;154:1618-35.

170. Lattimer G, Rhodes LV III, Salventi JF, Cepil BR. Isolation of Legionella pneumophila from clinical specimens: salutary effects of lung tissue dilution. *Am Rev Respir Dis* 1980;122:101-5.
171. Kohler RB, Zimmerman SE, Wilson E, Allen SD, Edelstein PH, Wheat LJ, White A. Rapid radioimmunoassay diagnosis of Legionnaires' disease. Detection and partial characterization of urinary antigen. *Ann Intern Med* 1981;94:601-5.
172. Berdal BP, Farshy CE, Feeley JC. Detection of Legionella pneumophila antigen in urine by enzyme-linked immunospecific assay. *J Clin Microbiol* 1979;9:575-8.
173. Tilton RC. Legionnaires' disease antigen detected by enzyme-linked immunosorbent assay. *Ann Intern Med* 1979;90:697-8.
174. Sedgwick AK, Tilton RC. Identification of Legionella pneumophila by latex agglutination. *J Clin Microbiol* 1983;17:365-8.
175. Cherry WB, Pittman B, Harris PP, Hebert GA, Thomason BM, Thacker L, Weaver RE. Detection of Legionnaires' disease bacteria by direct immunofluorescent staining. *J Clin Microbiol* 1978;8:329-38.
176. Broome CV, Cherry WB, Winn WC Jr, MacPherson BR. Rapid diagnosis of Legionnaires' disease by direct immunofluorescent staining. *Ann Intern Med* 1979;90:1-4.
177. Bibb WF, Arnow PM, Dellinger DL, Perryman SR. Isolation and characterization of a seventh serogroup of Legionella pneumophila. *J Clin Microbiol* 1983;17:346-8.
178. Wilkinson HW, Cruce DD, Broome CV. Validation of Legionella pneumophila indirect immunofluorescence assay with epidemic sera. *J Clin Microbiol* 1981;13:139-46.
179. Wilkinson HW, Reingold AL, Brake BJ, McGiboney DL, Gorman GW, Broome CV. Reactivity of serum from patients with suspected legionellosis against 29 antigens of Legionellaceae and Legionella-like organisms by indirect immunofluorescence assay. *J Infect Dis* 1983;147:23-31.
180. Wilkinson HW, Fikes BJ, Cruce DD. Indirect immunofluorescence test for serodiagnosis of Legionnaires' disease: Evidence for serogroup diversity of Legionnaires disease bacterial antigen and for multiple specificity of human antibodies. *J Clin Microbiol* 1979;9:379-83.
181. Farshy CE, Klein GC, Feeley JC. Detection of antibodies to Legionnaires' disease organism by microagglutination and micro-enzyme-linked immunosorbent assay tests. *J Clin Microbiol* 1978;7:327-31.
182. Farshy CE, Cruce DD, Klein GC, Wilkinson HW, Feeley JC. Immunoglobulin specificity of the microagglutination test for the Legionnaires' disease bacterium. *Ann Intern Med* 1979;90:690.

184. Lennette DA, Lennette ET, Wentworth BB, French MLV, Lattimer GL. Serology of Legionnaires disease: comparison of indirect fluorescent antibody, immune adherence hemagglutination, and indirect hemagglutination tests. *J Clin Microbiol* 1979;10:876-9.
185. Soriano F, Aguilar L, Gomez Garces JL. Simple immunodiffusion test for detecting antibodies against Legionella pneumophila serotype 1. *J Clin Microbiol* 1982;15:330-1.
186. Yonke CA, Stiefel HE, Wentworth BB, Wilson DL. Prevalence of antibody to serogroups 1-4 of Legionella pneumophila: a seroepidemiologic study using the indirect hemagglutination test. *Am J Epidemiol* 1982;115:633-9.
187. Horwitz MA, Silverstein SC. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. *J Clin Invest* 1983;71:15-26.
188. Morris GK, Patton CM, Feeley JC, Johnson SE, Gorman G, Martin WT, Skaliy P, Mallison GF, Politi BD, Mackel DC. Isolation of Legionnaires' disease bacterium from environmental samples. *Ann Intern Med* 1979;90:664-6.
189. Morris GK, Skaliy P, Patton CM, Feeley JC. Method for isolating Legionnaires' disease bacterium from soil and water samples. In: Jones GL, Hebert GA, eds. "Legionnaires": the disease, the bacterium and methodology. Atlanta: Center for Disease Control, 1979;86-90.
190. Bopp CA, Sumner JW, Morris GK, Wells JG. Isolation of Legionella spp. from environmental water samples by low-pH treatment and use of a selective medium. *J Clin Microbiol* 1981;13:714-9.
191. Edelstein PH, Snitzer JB, Bridge JA. Enhancement of recovery of Legionella pneumophila from contaminated respiratory tract specimens by heat. *J Clin Microbiol* 1982;16:1061-65.
192. Brenner DJ. Impact of modern taxonomy on clinical microbiology. *ASM News* 1983;49:58-63.
193. World Health Organization. Bacterial nomenclature. *Weekly Epidemiological Record*. 1981;56:399.
194. Brenner DJ, Feeley JC, Feldman RA. Confusion in bacterial nomenclature. *ASM News* 1983;48:511-2.
195. Bowdoin CD. A new disease entity (?). *J Med Assoc Ga* 1942;31:437-8, 442.
196. Daniels WB, Grennan HA. Pretibial fever. An obscure disease. *JAMA* 1943;122:361-5.
197. Tatlock H. Studies on a virus from a patient with Fort Bragg fever (Pretibial fever). *J Clin Invest* 1974;26:287-97.

198. Tatlock H. Clarification of the cause of Fort Bragg fever (pretibial fever)--January 1983. *Rev Infect Dis* 1982;4:157-8.
199. Gochenour WS Jr, Smadel JE, Jackson EB, Evans LB, Yager RH. Leptospiral etiology of Fort Bragg fever. *Public Health Rep* 1952;67:811-3.
200. Tatlock H. A rickettsia-like organism recovered from guinea pigs. *Proc Soc Exp Biol Med* 1944;57:95-9.
201. Pasculle AW, Myerowitz RL, Rinaldo CR Jr. New bacterial agent of pneumonia isolated from renal-transplant recipients. *Lancet* 1979;2:58-61.
202. Rogers BH, Donowitz GR, Walker GK, Harding SA, Sande MA. Opportunistic pneumonia: a clinicopathological study of five cases caused by an unidentified acid-fast bacterium. *N Engl J Med* 1979;301:959-61.
203. Hebert GA, Moss CW, McDougal LK, Bozeman FM, McKinney RM, Brenner DJ. The rickettsia-like organisms TATLOCK 91943) and HEBA (1959): bacteria phenotypically similar to but genetically distinct from Legionella pneumophila and the WIGA bacterium. *Ann Intern Med* 1980;92:45-52.
204. Hebert GA, Thomason BM, Harris PP, Hicklin MD, McKinney RM. "Pittsburgh pneumonia agent": A bacterium phenotypically similar to Legionella pneumophila and identical to the TATLOCK bacterium. *Ann Intern Med* 1980;92:53-4.
205. Hebert GA, Steigerwalt AG, Brenner DJ. Legionella micdadei species nova: Classification of a third species of Legionella associated with human pneumonia.
206. Gorman GW, Yu VL, Brown A, Hall JA, Corcoran LK, Martin WT, Bibb WF, Morris GK, Magnussen MH, Fraser DW. Isolation of Pittsburgh pneumonia agent from nebulizers used in respiratory therapy. *Ann Intern Med* 1980;93:572-3.
207. Stout J, Yu VL, Vickers RM, Shonnard J. Potable water supply as the hospital reservoir for Pittsburgh pneumonia agent. *Lancet* 1982;1:471-2.
208. Dowling JN, Weyant RS, Pasculle AW. Bactericidal activity of antibiotics against Legionella micdadei (Pittsburgh pneumonia agent). *Antimicrob Agents Chemother* 1982;22:272-6.
209. Dowling JN. Clinical aspects of Pittsburgh pneumonia. In: Schlessinger D, ed. *Microbiology-1981*. Washington, D.C.: American Society for Microbiology, 1981:161-164.
210. Cordes LG, Wilkinson HW, Gorman GW, Fikes BJ, Fraser DW. Atypical Legionella-like organisms: fastidious water-associated bacteria pathogenic for man. *Lancet* 1979;2:927-30.

211. Brenner DJ, Steigerwalt AG, Gorman GW, Weaver RE, Feeley JC, Cordes LG, Wilkinson HW, Patton C, Thomason BM, Lewallen Sasseville KR. Legionella bozemanii sp. nov. and Legionella dumoffii sp. nov.: classification of two additional species of Legionella associated with human pneumonia. *Current Microbiology* 1980;4:111-6.
212. Lewallen KR, McKinney RM, Brenner DJ, Moss CW, Dail DH, Thomason BM, Bright RA. A newly identified bacterium phenotypically resembling, but genetically distinct from, Legionella pneumophila: an isolate in a case of pneumonia. *Ann Intern Med* 1979;91:831-4.
213. Harris PP, Aufdemorte T, Ewing EP, Johnson JE, Tio FO. Fluorescent-antibody detection of Legionella dumoffii in a fatal case of pneumonia. *J Clin Microbiol* 1981;13:778-80.
214. Morris GK, Steigerwalt, Feeley JC, Wong ES, Martin WT, Patton CM, Brenner DJ. Legionella gormanii sp. nov. *J Clin Microbiol* 1980;12:178-21.
215. McKinney RM, Porschen RK, Edelstein PH, Bissett ML, Harris PP, Bondell SP, Steigerwalt AG, Weaver RE, Ein ME, Lindquist DS, Kops RS, Brenner DJ. Legionella longbeachae species nova, another etiologic agent of human pneumonia. *Ann Intern Med* 1981;94:739-43.
216. Bibb WF, Sorg RJ, Thomason BM, Hikclin MD, Steigerwalt AG, Brenner DJ, Wulf MR. Recognition of a second serogroup of Legionella longbeachae. *J Clin Microbiol* 1981;14:674-7.
217. Cherry WB, Gorman GW, Orrison LH, Moss CW, Steigerwalt AG, Wilkinson HW, Johnson SE, McKinney RM, Brenner DJ. Legionella jordanis: a new species of Legionella isolated from water and sewage. *J Clin Microbiol* 1982;15:290-7.
218. Edelstein PH, Brenner DJ, Moss CW, Steigerwalt AG, Francis EM, George WL. Legionella wadsworthii species nova: a cause of human pneumonia. *Ann Intern Med* 1982;97:809-13.
219. Orrison LH, Cherry WB, Tyndall RL, Fliermans CB, Gough SB, Lambert MA, McDougal LK, Bibb WF, Brenner DJ. Legionella oakridgensis: unusual new species isolated from cooling tower water. *Appl Environ Microbiol* 1983;45:536-45.
220. Herwaldt LA, Gorman G, Hightower AW, Brake B, Wilkinson H, Boxer PA, McGrath T, Brenner D, Moss CW, Broome CV. Pontiac fever in an engine assembly plant. In: American Society for Microbiology. Program and abstracts, Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology, 1982:82.